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 Congenital heart disease (CHD) is the most common birth defect, affecting 
approximately 1% of all live births. The population of adults with CHD has surpassed 
the prevalence of pediatric CHD due to remarkable achievements in medical care in the 
last few years, not only diagnostic but therapeutic as well. The etiology of CHD follows 
a multifactorial model, in which a complexity of genes and non-genetic factors interact. 
However, the precise genetic, epigenetic and environmental mechanisms for these 
perturbations remains poorly understood, despite the recent advances in genetic 
knowledge associated to CHD.  
 This review has the aim to explore the etiology of CHD, namely genetics, 
including syndromic and nonsyndromic cardiac defects, familiar risk and environmental 
factors discovered to date. This information is vital to offer a better health management 
and family planning to the patients and their families. Therefore, parental counselling, 
echocardiographic and genetic testing, as well as, prenatal screening will also be 
addressed. A brief review of the CHDs most reported in etiological studies, including 
epidemiology, pathology and phenotype, will be approached as well. 
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 As cardiopatias congénitas (CC) são o defeito mais comum à nascença, afetando 
aproximadamente 1% de todos os nados-vivos. A população de adultos com CC 
ultrapassou a prevalência da população pediátrica, devido aos avanços notáveis dos 
cuidados médicos nos últimos anos, não só ao nível diagnóstico como também 
terapêutico. A etiologia das CC’s segue um modelo multifactorial, no qual uma 
complexidade de genes e fatores não genéticos interagem entre si. Contudo, ainda pouco 
é conhecido sobre os mecanismos genéticos, epigenéticos e ambientais precisos para 
estas doenças, apesar dos avanços recentes no conhecimento genético associado às 
CC’s.  
 Esta revisão tem como objectivo explorar a etiologia das CC’s, nomeadamente 
genética, incluindo defeitos cardíacos sindrómicos e não-sindrómicos, risco familiar e 
factores ambientais descobertos até à data actual. Esta informação é vital para oferecer 
melhores cuidados de saúde e planeamento familiar aos pacientes e suas famílias. Por 
esse motivo, temas como o aconselhamento parental, testes de rastreio genético e 
ecocardiográfico, bem como pré-natal, vão ser abordados. Será também apresentado um 
breve resumo das CC’s mais referidas nos estudos etiológicos, incluindo epidemiologia, 
patologia e fenótipo. 
 
Palavras-chave: Cardiopatias congénitas; sindrómico; não-sindrómico; etiologia; 
genética; risco familiar; factores ambientais; aconselhamento genético; testes de rastreio 
pré-natal; testes genéticos. 







AS Aortic Stenosis 
ASD Atrial Septal Defect 
AVSD Atrioventricular Septal Defect 
BAV Bicuspid Aortic Valve 
CoA Coarctation of the aorta 
CHD Congenital Heart Disease 
CHF Congestive Heart Failure 
CNV Copy Number Variation 
DORV Double-outlet right ventricle 
EA Ebstein´s anomaly 
HLHS Hypoplastic Left Heart Syndrome 
IAA Interruption of the aortic arch 
PDA Patent Ductus Arteriosus 
PPS Peripheral Pulmonary Stenosis 
PVS Pulmonary Valve Stenosis 
SNP Single Nucleotide Polymorphism 
SVAS Supravalvular Aortic Stenosis 
TA Tricuspid Atresia 
TGA Transposition of the great arteries 
TAPVR Total anomalous pulmonary venous return 
PAPVR Partial anomalous pulmonary venous return 
TOF Tetralogy of Fallot 





 Congenital heart disease (CHD) is the most common birth defect, accounting for 
28% of all congenital malformations.
1
 There is a variety of genes, inheritance patterns 
and other factors, which may have a role in the cause of CHD. Therefore, it is 
considered a multifactorial disease, in which the interaction between genes and the 
environment is still poorly understood. The phenotypes of cardiac disease can range as 
well from the simplest defect, like a small ASD without other comorbidities, to the most 
complex ones, which may lead to cyanosis and consequently to poor survival after birth.  
 The interest in exploring the etiology factors of CHD, including inheritance 
patterns, familiar recurrence risks, environmental factors and available screening and 
diagnostic tools, is of paramount importance. Taking this knowledge into consideration, 
professionals can provide the best counselling to patients and their families regarding 
prevention, diagnosis and treatment of CHD. As such, discovery of the causes for CHD 
is vital not only for research but also to the healthcare of these patients. 
 This review has the purpose to reunite the discoveries to date regarding all the 
etiology factors of CHD mentioned above, and approach parental counselling, genetic 
testing and prenatal screening of CHD. 
 
Epidemiology
In CHD, the incidence and prevalence quantifications are difficult to measure 
accurately due to nonstandardized definitions of qualifying pathologies, geographic 
variability and nonuniform screening methods. The average incidence of CHD is 
calculated in 8 per 1,000 live births, varying between 1.2 per 1.000 (Columbia) and 17 
per 1,000 (Iceland), according to a large systematic review from studies worldwide.
2
 
Another study reports an incidence between 7 to 10 per 1,000 live births, excluding 
patent foramen ovale and bicuspid aortic valve (BAV), and 30 per 1000, including 
BAV.
3
 The largest population study is from EUROCAT, the European Registry of 
Congenital Anomalies, which collects data from 20 countries and a population of over 
18 million births. The average incidence of CHD found in live infants one week after 
birth was 6.4 per 1,000. 
4
 
Reported total CHD birth prevalence increased substantially over time, from 0.6 
per 1,000 live births in 1930 to 1934 to 9.1 per 1,000 live births after 1995. It is 




adults are living with CHD.
5
 Considering that the worldwide annual birth rate is around 
150 million births, it represents a major public health issue. Asia reported the highest 
CHD birth prevalence, with 9.3 per 1,000 live births, with relatively more pulmonary 
outflow obstructions and fewer left ventricular outflow tract obstructions. In Europe, the 
total CHD birth prevalence was significantly higher than in North America (8.2 vs. 6.9 
per 1,000 live births).
6
 As a result, CHD complicates around 1% of all live births in the 
general population, but occurs more frequently in the offspring (about 4-10%, 
depending on maternal CHD type) of women with CHD.
7
  
The population of adults with CHD has been growing at a rampant rate, 
surpassing the static prevalence of pediatric CHD with a ratio of 2:1. It is estimated that 
more than 90% of afflicted neonates and children now reach adulthood due to the 
remarkable advances over the last 60 years in diagnostic methods, medical 
management, interventional techniques, contemporary surgical procedures and 
perioperative care.
7,8
 It has been reported as well an increased incidence of simpler 
defects in developed countries, which might reflect an enhanced sensitivity in detecting 
milder forms of CHD combined with a reduction in the incidence of severe defects, due 
to pregnancy termination after prenatal diagnosis.
8
 From 1987 to 2005 was reported 
more than 30% reduction in mortality among these patients and a 67% reduction among 
children with complex disease.
9
 In the same period, the median age of death increased 
from 60 to 75 years and from 2 to 23 years in those with severe defects.
9
  
About a quarter of those requiring treatment will need surgery in the first year of 
life.
10
 Most infants and children requiring single interventions can expect to lead a near 
normal life. A small group of infants with complex lesions require multiple surgical 
procedures, intensive support and close monitoring during the first few years of life, 
although their quality of life may still be good. Because true surgical cures are rare, and 
all repairs, be they palliative or corrective, may leave residua, sequelae, or 
complications, most require some degree of lifetime expert surveillance. 
Women with CHD may now frequently successfully bear children after 
competent repairs. Although they are at increased risk for peri- and postpartum 
complications, maternal CHD is generally not considered an absolute contraindication 
to pregnancy unless the mother has high-risk features, namely cyanosis, pulmonary 
hypertension, decompensated heart failure, arrhythmias, aortic aneurysm, among others.  
Consultation with an adult CHD expert is warranted for all females with CHD who 





Ongoing efforts to increase awareness, resources, the number of specialty centers 






The anatomic and physiologic changes in the heart and circulation due to any 
specific CHD lesion are not static but rather progress from prenatal life to adulthood. 
Malformations that are benign or escape detection in childhood may become clinically 
significant in the adult.
7
 
Congenital heart diseases can be divided into: (1) left-to-right shunt lesions, such 
as atrial septal defect (ASD), ventricular septal defect (VSD), atrioventricular septal 
defect (AVSD), patent ductus arteriosus (PDA) and partial anomalous pulmonary 
venous return (PAPVR); (2) Obstructive lesions, such as pulmonary valve stenosis 
(PVS), aortic stenosis (AS), coarctation of the aorta (CoA) and interruption of the aortic 
arch (IAA); (3) and cyanotic defects, such as transposition of the great arteries (TGA), 
tetralogy of Fallot (TOF), total anomalous pulmonary venous return (TAPVR), tricuspid 
atresia (TA), hypoplastic left heart syndrome (HLHS), Ebstein´s anomaly (EA), truncus 
arteriosus, single ventricle, double-outlet right ventricle (DORV) and heterotaxy. 
Conotruncal defects include TGA, TOF, truncus arteriosus, DORV and IAA.   
According to their prognosis, CHD malformations can be divided into simple 
(Table 1), intermediate (Table 2) or complex (Table 3).
7
 This classification was created 
in order to stratify the CHD according to their severity and consequently suggest when 
cardiology consultation or advanced CHD specialty care is needed. Simple defects 
generally are single lesions with a shunt or a valvular malformation. These patients 
often may be managed by a well-informed internist or general cardiologist, although 
consultation with a specifically trained adult congenital cardiologist is occasionally 
advisable.  Intermediate defects may have two or more simple defects and should have 
an initial consultation and subsequent occasional intermittent follow-up with an adult 
CHD specialist. Complex defects generally have components of an intermediate defect 
plus more complex cardiac and vascular anatomy, often with cyanosis, and frequently 
with transposition complexes. These patients should virtually always be managed in 
conjunction with an experienced specialty adult CHD center.
7
 Specific heart defects will 




































Simple adult congenital heart disease 
Native disease 
Uncomplicated congenital aortic valve disease 
Mild congenital mitral valve disease 
Uncomplicated small atrial septal defect 
Uncomplicated small ventricular septal defect 
Mild pulmonic stenosis 
 
Repaired conditions 
Previously ligated or occluded ductus arteriosus 
Repaired secundum or sinous venosus atrial septal defect without residua 
Repaired ventricular septal defect without residua 
Table 1. Simple adult CHD. Source: adapted from Kasper et al. (2015)7 
Intermediate complexity congenital heart disease 
Ostium primum or sinous venosus atrial septal defect 
Total or partial anomalous pulmonary venous drainage 
Atrioventricular canal defects (partial or complete) 
Complicated ventricular septal defect (e.g., absent or abnormal valves or with 
associated obstructive lesions, aortic regurgitation) 
Coarctation of the aorta 
Moderate to severe pulmonic valve stenosis 
Infundibular right ventricular outflow obstruction of significance 
Moderate to severe pulmonary valve regurgitation  
Moderate to large patent ductus arteriosus (nonclosed) 
Sinus of Valsalva fistula/aneurysm 
Subvalvular or supravalvular aortic stenosis  
Table 2. Intermediate Complexity CHD. Source: adapted from Kasper et al. (2015)7 
Complex adult CHD 
Cyanotic congenital heart diseases (all forms) 
Eisenmenger’s syndrome 
Ebstein’s anomaly 
Tetralogy of Fallot or pulmonary atresia (all forms) 
Transposition of the great arteries 
Single ventricle; tricuspid or mitral atresia 
Double-outlet ventricle 
Truncus arteriosus 
Fontan or Rastelli procedures  





The etiology of CHD remains to be elucidated. In 1968, a hypothesis of 
multifactorial etiology was proposed, in which the environment and genetic factors 
interact with each other to cause CHD.
11
 A few years later, several separate 
environmental and genetic causes have been identified.
12,13
 The prevailing model 
involves variations in many different genes, each of which contributes only a small 
amount to the individual’s susceptibility to a particular condition. These interact with 
each other and with environmental factors to raise the likelihood that an individual will 
have CHD. Most sporadic cases of CHD (isolated cases of CHD without a family 
history of the condition) would fall into this category.
10
 
 Efforts have been made to explore the genetic and environmental factors that 
may lead to an increased risk of CHD in order to offer a better health management and 
family planning to the patients and their families, so that the risk of recurrence in the 
children of patients with CHD can be assessed. It may help as well identify possible 
complications and risk factors for surgery or treatment, as patients with genetic 




Although advances in understanding genetic risk factors have been made, little is 
known about nongenetic risk factors for the development of CHDs. Notwithstanding 
these facts, preventive strategies have been designed and instituted based on the 
information  available, and parents are counseled regarding their risk of having an 
affected child.
12
 Approximately 20% of the cases result from known causes, such as 
chromosomal anomalies, Mendelian syndromes, nonsyndromic single gene disorders 
and teratogens. The proportion of syndromic phenotypes with extracardiac 
manifestations can rise up to 30% of patients diagnosed with CHD, according to some 
authors.
15
Recognized chromosomal aberrations and mutations of single genes account 
for less than 10% of all cardiac malformations.
7
 Down syndrome and velocardiofacial 
syndrome are the most commonly seen syndromes in patients with CHD. The other 
80% is multifactorial between genetic and environmental contributors.
10
 Currently, 
more than 40 genes have been linked to nonsyndromic forms of CHD.
16
 Their 
contribution to CHD remains unknown but is presumed to be relatively small. Although 
cardiac defects can occur in the setting of multiple birth defects as part of a syndrome, 






Genetics of congenital heart disease 
 Genetic abnormalities appear to be the primary cause of CHD but identifying 
precise defects has proven challenging, principally because CHD is a complex genetic 
trait. In the last few years, the novel genetic testing technologies, such as next-
generation DNA sequencing, allowed the discovery of new candidate genes that may be 
involved in cases of CHD with unknown etiology.
13
 The human cardiovascular genetics 
is in the early phase of gene discovery. Molecular genetic studies, in the past two 
decades, have observed families with multiple affected individuals and have provided 
insights into the genetic causes of several forms of CHD. Thanks to these discoveries, it 
was demonstrated that the genetic contributions to CHD are more important than it was 
believed in the past. Embryos, fetuses, children and adults are being genetically tested 
in both research and clinical setting and it is expanding swifter than are the surveillance 
programs, for example.  
For the clinician caring for a child with CHD, it is very important to determine 
whether there is an underlying genetic pattern, because there may be extra-cardiac 
involvement, as well as prognostic information for clinical outcomes, important genetic 
reproductive risks and other family members may benefit from genetic testing.
17  
 
Insights in developmental biology 
CHD is a disorder resulting from abnormal heart development, so it is likely that 
defects in the genetic control of cardiac development underlie a majority of CHD.
18
 
Molecular pathways have been identified that orchestrate formation of primordial 
cardiogenic fields, that shape the cardiac crescent and linear heart tube, and that drive 
atrial, ventricular, inflow and outflow tract morphogenesis.
19
 It is difficult to estimate 
the number of genes required for cardiac development, especially since some essential 
cardiac genes, such as those involved in Hedgehog signaling, are also essential in very 
early, essential developmental processes that can obscure the cardiac phenotype. 
Defects in these general developmental genes may result in very early lethality, or 
instead, manifest as complex syndromes that have CHD as an important component.
18
 
Cells destined to become the heart originate from the mesoderm and to a smaller 
extent the neural crest. The genetic network regulating cardiac and regional cardiac 






The first major morphogenetic event in heart development is heart looping. The 
left-right (LR) asymmetry of the heart depends on global LR positional information 
generated by cilia during gastrulation. Defects in genes encoding ciliary function 
underlie many mouse models of heterotaxy 
20
 and ciliary defects have been identified in 
some humans with heterotaxy. The LR axis is initiated at a transient, evolutionary 
conserved ciliated structure called the Left-Right Organizer (LRO). LRO function 
depends on the extensive set of genes required for ciliogenesis, motility and signaling. 
Subsequent to heart looping, the T-Box transcription factors TBX 2,3,18, and 20 play a 
prominent role in specifying ventricular identity. Recent studies have shown that Tbx2 
plays a key role in the formation of the AV canal, the left ventricular base, and the 
cardiac conduction system.
21




The formation of the atrioventricular valves depends on the domains of 
endocardium that are fated to undergo epithelial-mesenchymal transformation (EMT). 
Genes involved in valve development include ones that are required for EMT, such as 
the TGFp family, and others not required in EMT such as NFATC1 and others that lie 
within the “Down Syndrome critical region”. It is interesting to note that patients with 
Down syndrome have a high frequency of atrioventricular septal defects (AVSDs) that 
are phenotypically more uniform than nonsyndromic AVSDs, and that the Down 
Syndrome-associated AVSDs usually respond remarkably well to surgical repair.
18
 
As we can see, the integration of insights from developmental biology has 
informed why some human CHD mutations produce specific clinical phenotypes. For 
example, mutations in ZIC3 cause cardiac laterality defects that are often accompanied 
by visceral heterotaxy, an association that is explained by evidence that ZIC3 
transcriptionally activates NODAL, a critical morphogen that is required for left-right 
patterning throughout the embryo.
23
 Mutations in GATA4 typically cause ASDs, but 
because a subset of these mutations disrupts GATA4-SMAD4 interactions that are 
critical for valve development, some patients have AVSDs.
24
 Mutations in NKX2-5 and 
TBX5 cause cardiac malformations that are associated with electrophysiologic deficits, 




There is great genotype-phenotype variability, that is, one single mutation can 
lead to multiple cardiac phenotypes. This was observed in studies including humans and 




heterozygous deletion of Tbx1 (model of DiGeorge syndrome) have a specific defect in 
the development of the 4
th
 aortic arch early in the development. Remarkably, as 
development proceeds, a number of pups remodel their aorta to approximate normal, 
while others progress to severe aortic abnormalities.
26
 
Familial CHD mutations occur as autosomal dominant, autosomal recessive, or 
X-linked traits that are expressed with high penetrance and with variable clinical 
manifestations.
16
 An evolutionary perspective of CHD mutations predicts that reduced 
reproductive fitness and early mortality would cause substantial negative selection that 
eliminates CHD mutations from human populations. If autosomal dominant or X-linked 
mutations make a significant contribution to the population prevalence of CHD, many 
must be de novo mutations, resulting in sporadic CHD.
16
 Far less is known about 
recessive models in CHD.
16
 Parental consanguinity (especially first-cousin marriages) 
significantly increases CHD risk,
27
 which supports that recessive mutations also cause 
CHD. The same mutant genes can be associated with different cardiac defects, and 
different cardiac defects can be associated to the same gene. All this support a polygenic 
and multifactorial model of CHD.
16
 
Genetic findings associated with CHD will be presented, dividing them into 




 The trisomies (trisomy 21, 18, and 13) are the most common chromosomal 




Down syndrome, as well known as trisomy 21, is associated with AVSD, ASD, 
VSD and TOF (less common) in 40 to 50% of these patients.
3,10
 Extra-cardiac 
manifestations include characteristic facial dysmorphism, epicanthal fold, simian crease, 
conductive hearing loss, gastrointestinal defects, variable degrees of intellectual 
disability, hypotonia and joint laxity. The overall prevalence of Down syndrome has 
been estimated to be 1/700 live births, although it is highly dependent on maternal age 
and has decreased significantly as a result of routine prenatal testing.
29
  
Pulmonary hypertension develops more often and earlier in patients with CHD. 
Down syndrome does not increase surgical mortality and morbidity during the repair of 
the atrioventricular canal defect. The five-year survival rate is almost 70% for 
14 
 
surgically-corrected AVSDs in Down syndrome, being no different from that of 
nonsyndromic patients.
29
 Down syndrome is a significant risk factor for the 
development of a post-operative atrioventricular block. Echocardiograms should be 
performed in all patients at diagnosis, regardless of whether a fetal echocardiogram was 
performed 
30
 and it is recommended regular monitoring for signs and symptoms of 
congestive heart failure (CHF) at every visit if the patient has CHD.
30
 Conventional 
karyotyping is indicated in all patients to confirm the diagnosis.   
 A candidate gene resequencing approach of 26 genes in individuals with Down 
syndrome with either AVSDs or without CHD identified potentially damaging variants 
in almost 20% of individuals with Down syndrome with AVSDs but in only 3% of 
those with Down syndrome without CHD.
31
 Six genes were specifically implicated: 
COL6A1, COL6A2, CRELD1, FBLN2, FRZB, and GATA5. Pathway analysis with these 
six genes implicated VEGF-A signaling, which was known to have a role in 
atrioventricular valvuloseptal morphogenesis. 
 Patients with Edwards or Patau syndrome have poor survival: 80% and 90% die 
in first year, respectively.
17
Almost all patients with Edwards syndrome (Trisomy 18) 
have cardiac defects (90-100%), including VSD, ASD, PDA, DORV, TOF, CoA, 
HLHS, BAV, d-TGA and polyvalvular nodular dysplasia.
10,17
 Other clinical features 
include prenatal growth deficiency, distinctive facial features and overlapping fingers 
and toes. Patau syndrome (trisomy 13) is associated with CHDs in 80-100% of cases, 
namely ASD, VSD, PDA, polyvalvular disease, HLHS and laterality defects.
16,17
 
Orofacial clefts, postaxial polydactyly, microphthalmia are some of the other features.
16
 
 Turner syndrome is found in girls caused by the absence of, or structural 
anomalies in, one of the two X chromosomes (Monosomy X). The incidence of Turner 
syndrome is estimated to be approximately 1:2000 live female births.
29
 It includes 
diverse clinical features, including a short stature, webbed neck, bowed arms, primary 
amenorrhea and thus infertility, as well as cardiac and renal anomalies, although 
virtually any organ system can be affected. 
29
Conventional karyotyping is indicated in 
all Turner patients to confirm the diagnosis. This syndrome is associated in 25-45% of 
cases to CHD, mainly to BAV (16%) and CoA (11-14%)
32
 but, AS, HLHS
17
, partial 
anomalous pulmonary venous return (PAPVR) and VSD can also be found.
29
 Moreover, 
aortic dissection (1-2%), systemic hypertension (30-50%), and ischemic heart disease 
are of concern in adult Turner patients, and are often fatal and the leading causes of 
increased mortality.
33




aggressive management of hypertension is recommended if hypertension is detected. 
Therefore, all Turner patients should have a baseline cardiologic evaluation with an 
echocardiogram or cardiac magnetic resonance imaging (MRI), and be monitored by 
longitudinal imaging every 5-10 years even when an adult in order to assess their aortic 
diameters. Echocardiography is generally adequate to visualize the heart valves and 




Klinefelter syndrome (47,XXY) is associated with CHD in 50% of cases, 
namely ASD, PDA and mitral valve prolapse (MVP). Other features include tall stature, 




Cat eye syndrome is a rare condition caused by the short arm (p) and a small 
section of the long arm (q) of chromosome 22 (22pter-22q11) being present three 
(trisomic) or four times (tetrasomic) instead of the usual two times.
34
 Normally the 
inheritance is de novo, but it can be autosomal dominant. It is associated with TAPVR, 
PAPVR and TOF in more than 50% of cases.
16
 There is high variability in the 
phenotype; some clinical features are the coloboma of the iris, anal atresia, renal 
malformations and periauricular tags or pits.
16
  
Cri-Du-Chat syndrome is caused by a deletion in 5p15.2. The gene associated is 
CTNND2 and has only de novo inheritance. 10-55% of cases are associated with VSD, 
PDA, ASD and TOF. Other clinical features include microcephaly, prenatal and 
postnatal growth retardation, severe psychomotor and mental retardation, distinctive 
facial features (round face, widely spaced eyes, epicanthal fold) and high-pitched 
cry.
16,17
   
Pallister-Killian syndrome is an extremely rare genetic disorder and is due to the 
presence of the anomalous extra short arm of the chromosome 12. This leads to the 
development of tetrasomy 12p. Because not all cells have this defect, Pallister-Killian is 




Microdeletion syndromes with cardiac phenotypes show autosomal dominant 
inheritance, although the large proportion of the microdeletions arise de novo.
28
  
The most common segmental aneuploidy is the 22q11 microdeletion, usually 
arising de novo, which accounts for substantial 34% of truncus arteriosus and 16% of 
TOF.
3
 DiGeorge/velocardiofacial syndrome (VCFS) is caused by loss of part of 
16 
 
chromosome 22 (del22q11.2), which includes the gene TBX1. The incidence is 
estimated to be 1/4000 live births. Fluorescence in situ hybridization (FISH) has been 
widely used to confirm the diagnosis.
29
 Haploinsufficiency (loss of one of the two 
copies of the gene) of TBX1 is responsible for many of the clinical features of VCFS, 
including the cardiac phenotype.
35
 75-85% of patients with VCFS have CHD, which 
usually includes conotruncal defects, TOF (20%), interrupted aortic arch type B (13%), 
truncus arteriosus (6%), aortic arch anomalies and VSD.
10
 CHD is required for the 
diagnosis of the syndrome.
16
 The common 22q11.2 deletion and the associated TBX1 
mutations represent the most frequent genetic diagnosis in non-syndromic TOF as well. 
It was also found that AVSD associated with TOF is highly suggestive of trisomy 21 
and excludes 22q11.2 deletion.
36
 
In addition to cardiac defects, palatal defects including cleft palate and bifid 
uvula, and immunodeficiency are most frequently associated with significant clinical 
features. Each is identified in approximately 70-75% of cases.
29
  Other clinical findings 
include  hypocalcemia (50%), renal anomalies (30%), thymus and parathyroid aplasia or 
hypoplasia, hypertelorism, micrognathia, low-set posteriorly rotated ears, “fish mouth”, 
feeding and swallowing problems, hearing loss, seizures and skeletal anomalies. 
Learning disabilities and borderline mental retardation are common, and the mean IQ 
score in those affected is reported to be approximately 70-80.
37
 In addition, the 
incidence of psychiatric disorders, including schizophrenia, bipolar disorder, anxiety, 
and depression, is known to be increased.
37
  
All patients with 22q11.2 deletion syndrome should be evaluated with an 
echocardiogram and electrocardiogram at diagnosis.
29
 Moreover, diagnostic tests are 
recommended for all patients with an interrupted aortic arch and truncus arteriosus, 
even if they do not show the other physical phenotypes commonly seen in this 
syndrome. This is because the proportion of 22q11.2 deletion is particularly high in 
patients with these two anomalies, 50-89% of an interrupted aortic arch and 34-41% of 
truncus arteriosus.
17
 Various medical problems can occur in multiple organ systems 




Considerable attention is now devoted not only to deletion but also to 
microduplication of 22q11.2. It  may occur with a frequency approximately half of that 
of deletions.
39
 The phenotype of patients with microduplication 22q11.2 is extremely 






spectrum of CHD associated with microduplication 22q11.2 is vast, including 
conotruncal defects,VSD, HLHS, valvular anomalies and TAPVR, among others. 
Interestingly, there is highly variable inter- and intrafamilial expression even among 
family members with the same size duplication.
39
Consistent with the effects of these 
chromosomal duplications, Zweier et al. reported that TBX1 gain of function mutations 
produce human conotruncal malformations.
40
 
Williams-Beuren syndrome consists in a microdeletion (del 7q11.23), in which 
the elastin gene (ELN) resides. This deletion can be detected by FISH.
29
  
Haploinsufficiency for elastin in this syndrome is responsible for hernias, the husky 
voice and the cardiac defects (75-80%), mainly supravalvular aortic stenosis (SVAS). 
ELN can also be associated with non-syndromic familial SVAS, pulmonary valve 
stenosis (PVS), pulmonary artery stenosis (PAS) or AS.
10
 CHD is required for the 
diagnosis of the syndrome.
16 Other characteristics of this syndrome are elfin facies 
(100%), psychomotor retardation (75%), characteristic cognitive profile with loquacious 
personality (90%), skeletal and renal anomalies and idiopathic hypercalcemia (15%). Its 




Supravalvular aortic stenosis has been thought to be progressive, but recent 
reviews report that the lesion remains stable in the majority of patients, and the 
progression of stenosis is particularly associated with moderate to severe stenosis at 
diagnosis.
41
 Approximately 20% of patients require surgical or transcatheter 
interventions for cardiovascular anomalies during the follow-up period.
42
 Hypertension 
is also frequently developed in approximately 50% of Williams patients, and the risk for 
its development increases with age.
29
 Thus, all patients with Williams syndrome should 
be evaluated with an echocardiogram with a Doppler flow study. Moreover, the 
evaluations for the development of cardiovascular complications by regular imaging 
studies, electrocardiograms, and blood pressure measurements on an annual basis 
during childhood, and every 3-5 years in adulthood are recommended.
43
 
Jacobsen syndrome results from the deletion of the terminal region of the 
chromosome 11 (11q-). 43-70% are associated with CHD, such as HLHS, DORV, d-
TGA, AS and VSD. Growth and psychomotor retardation, thrombocytopenia, platelet 
dysfunction, widely spaced eyes, strabismus, broad nasal bridge, thin upper lip, 
prominent forehead are some of the features. A cardiac “critical region” has been 
identified in distal 11q that is thought to contain putative genes for CHD.
44
 It was 
18 
 
demonstrated  that loss of the murine analogue of the ETS-1 gene, located in the cardiac 
critical region of 11q, causes VSD and abnormal ventricular morphology in mice.
45
 The 
role of ETS-1 in CHD will likely be the subject of future investigation in patients with 
11q-as well as non-syndromic patients. 
 
Copy number variations (CNV) 
 Increasing attention is now being given to copy number variants (CNV) in CHD. 
They are variations in the number of copies of a specific section of DNA present in an 
individual. These variations consist in gains or losses of contiguous DNA ranging in 
size from 1 kb to several Mbs and they are considered as another type of chromosomal 
anomaly.
3
 These represent a significant source of inter-individual genetic variation that 
may explain the variable expression of inherited disorders, variable phenotypical 
presentation of disorders, and potentially non-syndromic CHD.
46
 These CNVs can 
either be inherited or de novo.
18
 Specific CNVs have in the past been associated with 
diseases such as autism and schizophrenia and, more recently, with CHD. Significant 
challenges remain in differentiating pathologic CNVs from benign polymorphic ones.
3
 
Certain CNVs are recurrent and at higher frequency in individuals with CHD, often 
ones that are also associated with extracardiac abnormalities. Exploration of genes 
disrupted in large CNVs may reveal further insights in the role of specific CNVs in the 
pathogenesis of CHD.
18
 The most relevant non-syndromic CNVs are represented in 
Table 4 (see below)
16
. 
 A genome-wide CNV study of various types of CHD compared more than 2,000 
CHD cases including around 800 with TOF to nearly 900 controls.
47
 They found a 
significant burden of rare loss CNVs >100 kb containing genes (OR 1.8; population 
attributable risk of nearly 3.5%). There was a trend towards greater ORs with increasing 
CNV deletion size and gene content. Significant association with WNT signaling was 
revealed, which was altered in a broad range of CHD. Examining CNVs that were 
recurrent, the authors confirmed prior observations of gain and loss CNVs, including 
GATA4 at 8p23.1 and deletions at 15q11.2 in 0.5% of cases, an OR of 8.2 compared to 
controls. The majority of rare de novo CNVs identified in CHD have paternal origin.
47
 
 10% of sporadic nonsyndromic TOF were found to harbor rare de novo CNVs, 
including recurrent CNVs at 1q21.1, 3p25.1, 7p21.3 and 22q11.2 regions.
48
 A recent 
study found that microduplications of the 1q21.1 region accounted for about 1% of the 




Table 4. CNVs associated with recurrent cases of nonsyndromic CHD.16 
in that region, was associated with a 10-fold increase in risk of TOF.
49
 Deletion 
of 1q21.1 was more common in cases of non-TOF CHD than in controls. 1q21.1 CNVs 
have previously been associated with other phenotypes such as autism, schizophrenia, 
and intellectual disabilities.
3
 In another study regarding TOF, more than 400 adults with 
TOF with or without pulmonary atresia (PA) but without known genetic abnormalities 
like the 22q11 deletion were studied.
50
 Large, rare CNVs (>500 kb) were more 
prevalent in cases compared to controls (8.8% vs. 4.3%) with mostly genomic gains. 
Especially when the CNVs contained genes, the subjects were more likely to have 
extracardiac abnormalities.  
 CNV’s were also associated with left ventricular outflow tract defects, including 
HLHS.
51,52
 Of interest, these rare CNVs were found to harbor genes relevant for 
angiogenesis. After filtering, the authors identified 25 putative candidate genes for left-
sided heart defects. 
 The role of CNVs in atrioventricular septal defects (AVSDs), both in patients 
with and without Down syndrome, was investigated.
53
 The authors concluded that larger 
rare CNVs altering chromosome 21 do not contribute significantly to the pathogenesis 
of AVSDs neither in patients without Down syndrome nor in patients with AVSDs and 
20 
 
Down syndrome. However, isolated sporadic AVSDs may be occasionally associated 
with large de novo CNVs outside of chromosome 21.
53
 
 Heterotaxy was also found associated with CNV’s. It consists in an asymmetric 
development along the left-right body axis, leading to thoracic and abdominal organ 
defects. More than 250 patients with heterotaxy and nearly 1000 controls were 
genotyped with SNP (Single Nucleotide Polymorphism) arrays.
54
 There were nearly 
two-fold more rare CNVs among the heterotaxy cohort compared to the controls (14.5% 
vs. 7.4%, respectively). In the 38 smaller CNVs identified, 14 of 61 genes altered were 
relevant to biological processes of relevance for left-right axis development: ciliary 
function, zinc finger transcriptions factors and TGF-β signaling. Five genes contained 
within CNV areas were shown to be significant. NEK2, ROCK2, TCGBR2, GALNT11, 
and NUP188 were verified by knockdown in Xenopus to produce laterality defects.
54
 
With new chromosome microarray technology (SNP microarrays and array 
comparative genomic hybridization)
55
 , further “cryptic” rearrangements, such as CNVs, 
will be unmasked to reveal loci critical for embryonic heart development. 
 
Mendelian syndromes 
 About 3%–5% of CHD can be attributed to Mendelian syndromes where a single 
mutation in the DNA results in pathological consequences, following a Mendelian 
inheritance pattern.
10
 Large multigenerational pedigrees demonstrating Mendelian 
inheritance of CHD are rare.
18
 These single gene syndromes show predominantly 
autosomal dominant inheritance with variable expressivity and pleiomorphic 




 Noonan syndrome is the second most common genetic syndrome of CHD, 
followed by Down syndrome.
29
 The estimated prevalence of this syndrome is 1/1000-
2500.
56
 It is an autosomal dominant disorder that can be caused by mutations in various 
genes, which are members of the RAS-MAPK pathway: PTPN11, SOS1, KRAS, RAF1, 
NRAS, BRAF, SHOC2, CBL and RIT1. Mutations in these genes can be identified in 
more than 70% of clinically diagnosed Noonan cases.
56
 Gain-of-function mutations in 
the PTPN11 account for 40–60% of all Noonan cases. Prenatal testing can be done 
when the fetus is at risk for inheriting a defined PTPN11 mutation from an affected 
parent.
17
 This gene is more prevalent among familial cases and among patients with 




mesenchymal transformation in the endocardial cushions, and thus leading to PVS.
57
 
Penetrance is nearly complete among those with PTPN11 mutations, although 
phenotypic variability within families can be substantial.
17
 RAF1 mutations show a 
higher prevalence of hypertrophic cardiomyopathy (HCM).
58
 Apart from PVS (50-65%) 
and HCM (20%), secundum ASD (6-10%), and more rarely,VSD, PDA and CoA are 
also asociated.
10
 CHD is present in 70–80% of cases. This syndrome encompasses 
variable extra-cardicac phenotypes including short stature and typical facial features. 
The main facial findings are hypertelorism with downslanting palpebral fissures, ptosis, 
and low-set posteriorly rotated ears. Other manifestations are a webbed neck, thorax 
deformity, cubitus valgus, mild developmental delay, cryptorchidism in males, feeding 
difficulties in infancy, bleeding tendency and lymphatic dysplasia.
56
 
  Pulmonary stenosis shown in Noonan syndrome is usually accompanied by 
dysplastic leaflets, thus interventional balloon dilation is difficult to perform and 
surgical correction is often required.
14
 The severity of the HCM can vary from mild to 
severe and can progress with age. Approximately 25% of patients with HCM die from 
heart failure in the first year of life.
29
 Accordingly, a clinical assessment, 
electrocardiogram, and echocardiogram should be performed at the initial evaluation in 
all suspected patients. There are no consensus guidelines for Noonan syndrome 
management and follow-up, however several review articles recommend repeated 
cardiologic evaluations every 2-5 years, even if the initial examination is normal.
56
 
 Alagille syndrome is an autosomal dominant disorder with an estimated 
prevalence of 1 in 70,000 newborns. It is caused by mutations in the JAG1 gene in more 
than 90% of cases. Another 7% have deletions on 20p12 that include the JAG1 and few 
people have mutations in NOTCH2.The JAG1 and NOTCH2 genes trigger Notch 
signaling between neighboring cells during embryonic development. The disruption of 
this signaling results in this syndrome.
59
 Patients suspected of having Alagille syndrome 
should undergo karyotype and FISH analysis and the finding of a deletion or 
chromosomal rearrangement can be diagnostic.
17
 JAG1 mutation analysis is clinically 
available for those patients whose karyotype and FISH analyses are normal. The cardiac 
defects associated are peripheral pulmonary stenosis (PPS), PVS, TOF and, more rarely, 
ASD.
10,16,17
 The cardiac phenotype shows in 85-95% of the cases.
16,17
 The finding of 
PPS or hypoplasia of the branch pulmonary arteries in a child, alone or in combination 
with TOF, should prompt consideration of testing for Alagille syndrome.
17
 The 
phenotype includes biliary atresia, cholestasis, skeletal abnormalities, ocular disease, 
22 
 
distinctive facial features (broad forehand, hypertelorism and underdeveloped 
mandible). Alagille syndrome should have cardiac, hepatic, ophthalmologic, orthopedic 




 Holt-Oram syndrome occurs in approximately 1 per 100 000 individuals and is 
caused by mutations in TBX5 on chromosome 12q24. 85% of the individuals have 
mutation de novo, although it is inherited in an autosomal dominant manner.
60
 It is 
always associated with upper limb deformity, namely preaxial radial ray malformation 
(eg, triphalangeal, hypoplastic, or absent thumb and/or radial dysplasia)
17
 and, in 80% 
of cases, with CHDs (ASD, VSD, AVSD and/or conduction defects).
16
 
 Mutational analyses of the TBX5 gene-coding regions will detect mutations in 
approximately three fourths of such patients.
17
 Management involves a 
multidisciplinary team of specialists in medical genetics, cardiology, orthopedics, and 
hand surgery. Surveillance is done by annual ECG for all individuals, annual Holter 
monitor for individuals with known conduction disease, and echocardiogram every one 
to five years for those with septal defects.
60
 In pregnancies at 50% risk (one parent 
affected), detailed high-resolution prenatal ultrasound examination may detect upper-
limb malformations and/or congenital heart malformations.
60
 Prenatal molecular genetic 
testing may be used to confirm a diagnosis if theTBX5 pathogenic variant has been 
identified in an affected relative.
60
 Blastocysts can be subjected to preimplantation 




 Char syndrome is caused by mutations in TFAP2B on chromosome 6p12. 
Phenotypically includes distinctive facial features (flat nasal bridge and nose tip, ptosis), 
hand deformities and PDA in term infants in 60-100% of these patients.
10,16
 
 Smith–Lemli–Opitz syndrome is an autosomal recessive disease caused by 
mutations in DHCR7.
62
 It causes a defect in the conversion of 7-dehydrocholesterol to 
cholesterol, which leads to a deficiency of cholesterol. This syndrome affects an 
estimated 1 in 20,000 to 60,000 newborns. This condition is most common in whites of 
European ancestry, particularly people from Central European countries such as 
Slovakia and the Czech Republic. It is associated witch CHDs in 45% of cases, namely 
AVSD, primum ASD, VSD and PAPVR.
10
 This condition is characterized by 
distinctive facial features, microcephaly, intellectual disability and behavioral problems, 




gastrointestinal tract and genitalia are also commonly affected. Infants with Smith-
Lemli-Opitz syndrome have hypotonia, experience feeding difficulties, and have growth 
retardation. Most have syndactyly and some have polydactyly.
62
 
 Costello syndrome is very rare (affects probably 200 to 300 people worldwide) 
and is caused by HRAS mutations on chromosome 11p15.5.
63
 Some people with signs 
and symptoms of Costello syndrome do not have an identified mutation in 
the HRAS gene. These individuals may actually have cardiofaciocutaneous syndrome or 
Noonan syndrome, which are caused by mutations in related genes. This condition is 
characterized by short stature, intellectual disability, loose folds of skin, unusually 
flexible joints, distinctive facial features including a large mouth, tight Achilles tendons, 
hypotonia, brain malformation, skeletal abnormalities, dental and vision problems. 
Heart defects occur in 63% of cases, typically PVS, HCM, and/or atrial tachycardia. 
Beginning in early childhood, these individuals have an increased risk of developing 




 Cardio-facio-cutaneous syndrome (CFCS) is also very rare (affects probably 200 
to 300 people worldwide). This syndrome is characterized by mental retardation, facial 
dysmorphisms (high forehead, short nose, hypertelorism, down-slanting palpebral 
fissures, eyelid ptosis, small chin and low-set ears), ectodermal abnormalities (dry skin, 
nevi, wrinkled palms and soles, sparse or absent eyelashes and eyebrows), failure to 
thrive and heart defects (71% of cases), namely PVS, ASD and HCM.
16
 Mutations in 
BRAF, MEK1/MEK2 and KRAS have been implicated in CFCS.
16
 CHD incidence, 




 The following syndromes are caused by mutations in chromatin remodeling 
genes. Genes involved in this function were found to be associated with CHD 
development, such as non-syndromic de novo mutations (see below). 
 CHARGE syndrome is caused by mutations in CHD7 in 2/3 of cases, and 
SEMA3E. It has an estimated prevalence of 1:10.000.
65
 CHARGE stands for coloboma 
of the eye, heart defect, atresia choanae, retarded growth and development, genital 
abnormality (micropenis and cryptorchidism), and ear abnormality (hypoplastic 
semicircular canals, mild to profound hear loss and abnormal middle and external 
ear). 25% of these patients have no cognitive impairment.
18
 Cardiac defects are 





 Kabuki syndrome is caused by mutations in  MLL2 in 55-80% of the cases 
(autosomal dominant pattern)
66
 and KDM6A (X-linked dominant pattern)
67
. It is 
associated with CHD in 31-55% of cases, namely CoA, ASD, VSD, TOF, PDA, HLHS 
and mitral stenosis (MS)
16
. The phenotype is characterized by a unique facial 
appearance (arched eyebrows, long eyelashes, long palpebral fissures, eversion of the 
lower lip at the outside edges, a flat, broadened tip of the nose and large protruding 
earlobes), growth retardation (postnatal dwarfism), intellectual disability, skeletal 
abnormalities, spinal deformities (scoliosis), cleft palate and recurrent otitis media. 
 Schinzel-Giedon syndrome is a very rare and severe condition caused by 
heterozygous mutation de novo of SETBP1 (chromosome 18q21.1). 
68
 Most affected 
individuals die before the age of ten and present severe mental retardation, neurological 
problems, such as seizures, feeding or hearing impairment, distinctive facial features 
(midface retraction, high protruding forehead, larger than normal fontanelles, 
hypertelorism and prominent ear lobes), skeletal abnormalities, genitourinary and renal 
malformations, and cardiac defects in 43% of cases. It is reported an increased 
prevalence of tumors, notably neuroepithelial neoplasia.
68
 
 Kleefstra syndrome is caused by the loss of EHMT1 on the chromosome 9q34.3. 
25% of individuals have mutations in the EHMT1 gene instead of a deletion
69
. This 
results in a lack of functional euchromatic histone methyltransferase 1 enzyme (histone 
modifier), and consequently impairs the control of activity of certain genes in many of 
body’s organs and tissues. Clinical features include conotruncal heart defects (50% of 
cases), developmental delay, intelectual disability, severely limited or absent speech, 
hypotonia, microcephaly and brachycephaly. Distinctive facial features include 
eyebrows that grow together in the middle (synophrys), hypertelorism, midface 
hypoplasia, anteverted nares, prognathism, everted lips and macroglossia. Affected 
individuals may have a high birth weight and childhood obesity, structural brain 
abnormalities, genitourinary abnormalities, seizures, and a tendency to develop severe 
respiratory infections. During childhood they may exhibit features of autism.
70
 
 Recent studies have implicated cilia in the etiology of CHD and suggest that 
some CHDs are part of the ciliopathy spectrum of disease (Figure 1).  
Nephronophthisis (NPHP) and several associated ciliopathies, Meckel-Gruber 
syndrome (MGS), Joubert syndrome (JS), and Senior-Loken syndrome (SLS), are 
characterized by a spectrum of phenotype, including renal cyst disease, retinal 




localize to the cilium or basal body 
have been linked to these four 
ciliopathies.
71
 Among these genes, 
NPHP2/INVS, NPHP3, NPHP4 and 
NPHP9/NEK8 can also lead to 
heterotaxy, situs inversus and CHDs. 
A partial deletion of Nphp2/Invs in 
mouse results in situs inversus while 
an interstitial deletion in humans has 
been linked to transposition of the great arteries (TGA).
72
 A complete loss of Nphp3 in 
mouse results in situs inversus and CHD, while NPHP3 mutations in humans have been 
linked to situs inversus, structural heart disease and polydactyly.
73
 NPHP4 mutations in 
humans are associated with heterotaxy.
74
Loss of Nphp9/Nek8 in mouse and zebrafish 
results in renal cyst formation and cardiac laterality defects
75
 while a homozygous 
nonsense mutation in humans results in cystic kidneys and CHD.
76
  
Ellis–van Creveld syndrome (EVCS) is a recessive skeletal dysplasia disorder 
that has been classified as a ciliopathy. EVCS is caused by mutations in EVC1 and 
EVC2 on chromosome 4p16. It is characterized by numerous defects, notably dwarfism, 
polydactyly, dysplastic nails and teeth, and CHD. Among EVCS patients with CHD 
(60%), 88% of affected individuals display a partial AVSD (primum ASD) and 
approximately 50% have an ASD producing a common atrium.
77
  
Heterotaxy syndrome has X-linked inheritance due to mutations in the ZIC3 
transcription factor and is tightly associated with CHD. It includes both cardiac 
(Dextrocardia, L-TGA, AVSD, TAPVR) and non-cardiac (eg, asplenia, polysplenia) 
manifestations.
18
 Asplenia, also known as right atrial isomerism, is seen predominantly 
in males and is associated with severe cyanotic CHD (TAPVR, AVSD, TGA, single 
ventricle) absence of spleen, bilateral trilobed lungs and right atria, symmetrical liver 
and intestinal malrotation. Most patients die before one year-old. Polysplenia (left atrial 
isomerism) is seen predominantly in females and can be diagnosed later, as it is less 
severe than the latter. It is associated with less severe CHD (PAPVR, TAPVR, 




Due to the role of motile cilia in determining lateral patterning, defects affecting 
ciliary motility machinery result in heterotaxy and CHD. Not surprisingly, 6.5% of 
Figure 1. Ciliary genes associated with syndromic CHDs18 
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patients with Primary Ciliary Dyskinesia (PCD), a disorder defined by abnormal ciliary 
motility in the airway epithelia, also display heterotaxy, which emphasizes the role of 
motile cilia in both disorders.
79
 Similarly, next-generation sequencing of 13 heterotaxy 
patients with ciliary dysfunction identified mutations in known dynein components of 
the ciliary motility machinery: DNAI1, DNAH5 and DNAH11.
80
 Novel heterotaxy-
causing genes were discovered, some of which have unanticipated roles in cilia 
structure and function.  
Mutations in genes that cause syndromic CHD can occasionally produce isolated 
heart malformations.
16
 Recurrent chromosomal or syndromic heart defects appear to 




Non-syndromal single gene disorders 
 In the past 20 years, research has primarily focused on gene discovery in non-
syndromal, familial forms of CHD. The proportion of cases falling into this group is 
still unknown, although it is presumed to be relatively small. Many of the genes 
reported to date encode transcription factors (proteins that regulate gene expression), 
receptors and ligands, but other types of proteins, particularly structural proteins such as 
cardiac actins and myosins, have also been implicated.
10
 More than 40 genes have since 
been associated.
16




. DNA testing for most 
of the genes for isolated congenital heart defects is unavailable except on a research 
basis; however, testing of some of these genes is transitioning from the research 
laboratory to clinical availability.
17
 
 Autosomal dominant inheritance is most common; however, the pathogenicity of 
the reported mutations and the role they play in disease phenotype and segregation is, in 
most cases, not very clear. An example of autosomal inheritance is left-sided obstructive 
disease ranging from BAV to HLHS due to mutations in NOTCH1.
82
 Although 
Mendelian recessive inheritance appears to contribute only a small fraction of the 
overall population burden of CHD, heterotaxy and AVSD can follow this pattern.
18
It is 
not the goal of this review to thoroughly address all of the genes discovered. Priority 





Table 5. Genes that cause isolated CHD; Phenotypes in parentheses denote syndromes and/or 
extracardiac manifestations associated with gene mutations.16  




The first two genes to be linked to non-syndromal CHD were NKX2-5 and 
GATA4.
10
 NKX2.5 mutations are associated with a range of lesions including ASDs 
associated with later-onset atrioventricular block, conotruncal defects (TOF, TGA, 
DORV), HLHS, Ebstein´s anomaly and VSD.
3,10
 Mutations in GATA4 have also been 
identified in patients with ASD and VSD.
13
 Both gain-of function and loss-of-function 
mutations in TBX20 result in familial ostium secundum ASDs and valve defects.
83
 A 
gain-of-function mutation was found which significantly enhanced transcriptional 
activity of two target genes, NKX2.5 and GATA4/5. These findings support the idea that 
the development of the atrial septum is a result of the complex interaction of multiple 
transcription factors.
83
 It is also interesting to mention the great similarity between 
genes associated to ASD and to VSD.
81
 
Non-syndromal single gene disorders often arise de novo such that the parents 
do not harbor the mutation and family history is negative for CHD. For highly penetrant 
mutations underlying severe forms of CHD, this mechanism is more likely since low 
reproductive fitness prior to the modern era provides strong negative selection against 
the accumulation of these mutations in the population.
3
 
Exome sequencing was performed for 362 parent-offspring trios in which the 
offspring had a sporadic conotruncal defect, left ventricular outflow track obstructive 
lesion, or heterotaxy, and was compared to comparable data from 264 control trios.
84
 It 
was found an excess burden of protein-altering mutations in genes highly expressed in 
the heart during heart development (OR of 2.53). These excess mutations accounted for 
10% of severe CHD cases and led to the estimate that approximately 400 genes underlie 
these cardiac lesions. After filtering to retain only variants most likely to be deleterious 
(nonsense, splice site and frameshift defects), the burden among CHD cases increased, 
attaining an OR of 7.50.
84
 
A highly significant enrichment of mutations among genes encoding proteins 
relevant for chromatin biology was observed, specifically the production, removal or 
reading of methylation of Lys4 of histone 3 (H3K4me).
84
 The phenotypes of the eight 
subjects harboring H3K4me de novo mutations was diverse, both with respect to the 
form of CHD and extracardiac manifestations. In addition, two independent de novo 
mutations were identified in SMAD2, which encodes a protein with relevance for 
demethylation of H3K27me. SMAD2 contributes to the development of the left-right 
body axis; both subjects harboring SMAD2 mutations had dextrocardia with unbalanced 




implicated in human neurodevelopmental disorders including autism and Rett 
syndrome, and cognitive impairment is a prominent feature of the majority of human 
syndromes associated with mutations in histone modification genes.
18
  
Mutations in non-coding regions, such as gene promoters, enhancers, locus 
control regions, microRNAs, and even intergenic regions are likely to be relevant for 
CHD causality, although not much has been discovered to date.
3
 A recent study focused 
on the identification of cis-regulatory elements for TBX5, the gene mutated in Holt-
Oram syndrome.
85
 A 700-kb region around TBX5 was scanned and three enhancer 
elements were sequenced in 260 unrelated individuals with ASDs, VSDs, or AVSDs, 
the predominant cardiac defects of Holt-Oram syndrome. It was identified a 
homozygous mutation in an enhancer of TBX5 in a patient with VSD. The authors 
provided strong evidence that this single nucleotide variant in a TBX5 enhancer alters 
expression of the gene during heart development. Given the population-wide frequency 
of this variant, it is estimated that 1/100 000 individuals would be homozygous for this 
variant, highlighting that a significant number of CHD associated 
with TBX5 dysfunction might arise from non-coding mutations 
in TBX5 heart enhancers.
85
 The challenges, well illuminated through this study, are how 
to prove causality definitively and how to scale such work as large numbers of 
candidate variants are identified through whole genome sequencing. 
 
Familiar risk 
 In a minority of cases, it is possible to provide a precise recurrence risk for 
CHD, based on known Mendelian inheritance in a family or on risk figures related to a 
chromosomal anomaly. The transmission risk for autosomal-dominant conditions such 
as Holt-Oram, Noonan, Alagille, and CHARGE syndromes is 50%. Chromosomal 
microdeletion is also associated with a 50% risk of transmission, as reported for both 
22q11.2 microdeletion and Williams syndrome. For recessive conditions, there is a 25% 
risk of both parents transmitting the disease-causing mutation to the offspring. 
However, Mendelian inheritance is observed in a relatively small proportion of families, 
so recurrence risk is usually based upon individual pedigree.
86
 
 In the absence of such information, empirical risk estimates must be used. The 
contribution of CHD family history to the overall prevalence of CHD in the populations 
was reported in 2.2%, and after the exclusion of chromosomal and extracardiac defects, 
the attributable risks were 4.2% and 3.6%, respectively.
28
 The low population-
30 
 
Table 7. Recurrence risk (RR) of different types of congenital heart 
disease (CHD)10 
attributable risk from a positive family history can be explained by a variety of factors: 
environmental risk factors for CHD, low-penetrance genes or gene combinations in 
susceptible individuals; susceptible embryos may develop a heart defect if other 
important genes along the same pathway in embryonic heart development are disturbed 
due to additional inherited gene mutations, de novo mutations, copy-number variations, 
or unfavorable maternal and intrauterine factors. 
28
 
 For the majority of patients with CHD and no family history or chromosomal 
abnormality, the risk of recurrence of CHD in offspring is around 3%.
86
The risk of 
recurrence for all types of CHD is threefold higher when a first-degree relative has 
CHD.
28
 Parental consanguinity is associated with a 2-3 fold increased offspring risk of 
CHD, likely due to the shared genetic variants among parents.
87
 
 Recurrence risks vary between different types of nonsyndromal CHD with 
multifactorial inheritance (Table 7).
10
  For most lesions, the reported recurrence risk in 
siblings of an affected individual, when neither parent is affected, is in the range of 1%-
6%.
10
 If more than one sibling is affected, the recurrence risk can increase to 10%.
10
 The 
recurrence risk in offspring of affected parents is generally significantly higher than that 
in siblings of affected individuals with unaffected parents. Further, if the mother is the 
affected parent, the risk of disease transmission is higher (2-20% vs. 1-5% if the father 
is the only affected).
10
 The reason for these differences is unknown, and it is difficult to 
reconcile them with known genetic mechanisms. However, maternal mitochondrial and 
cytoplasmatic inheritance has been considered among etiological mechanisms.
88,89
 
Generally, the recurrence risk 
increases if a parent rather than 
a sibling is affected, particularly 
when the affected parent is the 
mother.  
 Wang et al. (2014) 
analyzed a total of 61 familial 
pedigrees with CHD, and 134 
patients out of 761 family 
members had a diagnosis of 
CHD confirmed.
90
 The present 




prevalence of CHD in first-degree relatives (55/249, 22.0%) was significantly higher 
than that in second-degree relatives (18/526, 3.4%). Additionally, the recurrence rate of 
CHD in families in which the patient's mother or sister had CHD was significantly 
higher than in cases with the father or brother having CHD. This study confirmed the 
previous findings and was the first study to show that the recurrence risk was higher in 
patients whose sister was affected than in those whose brother was affected.
90
 
Interestingly, the approximated relative risk for CHD in 
monochorionic/diamniotic (MC/DA) twins was much stronger than in the general 
population (OR: 9.18, 5.51–15.29 ;P < .001).
91
 In addition, MC/DA twin gestations 
affected by twin-twin transfusion syndrome (TTTS) were more likely to be complicated 
by CHDs than those that did not have TTTS (OR: 2.78, 1.03–7.52).
91
 VSDs were the 
most frequent heart defects. PVS and ASD were significantly more prevalent in 
pregnancies complicated with TTTS.
91
 Therefore, fetal echocardiography may be 
considered for all MC/DA twin gestations.
91
 The relative risks in dizygotic twins and in 
singletons with a family history of any CHD in first-degree relatives were similar. The 
excess relative risk of CHD in monozygous twins and not in dizygotic twins indicates 
that twinning per se predisposes to CHDs, whereas the shared in utero conditions do not 
appear to play a big role.
91
  
The first study of the recurrence of CHD in the population of mothers referred 
for fetal echocardiography for a family history reported a total recurrence rate of 1.9% 
after one previously affected child and 10% after two previously affected children.
92
 
More recently, Fesslova et al. (2011) studied 1634 pregnancies screened prenatally by 
fetal echocardiography because of a family history of CHD in either first degree or more 
distant relatives.
89
 They pursued a final cardiologic examination of the child at least at 6 
months of age or later, in order to detect even those smaller anomalies that are difficult 
to visualize in the fetus.
93
 A higher recurrence rate of CHD than in previously published 
data was demonstrated (3.98%), mainly thanks to an improved detection of even milder 
forms of CHD both in utero and after birth.
89
 The recurrence rate would have been 
lower if it was considered only cases diagnosed during fetal life (3.2%), more similar to 
the results of Gill et al.
92
 Fesslova et al. (2011) considered as recurrent even the milder 
congenital heart lesions, such as small VSDs, discovered after birth that are often not 
detectable by fetal echocardiography as well as ASD that cannot usually be seen in the 
fetus, unless they are truly large.
89
 The occurrence of these defects is important for the 
32 
 
family that is usually very anxious after a previous experience with a cardiac problem 
and also for the own knowledge of the recurrence. 
 Concordance of recurrent CHD (the same subtype of CHD) within members of 
the same family can vary substantially between different types of CHD. Being exactly 
concordant means that the cardiac defect was identical between two family members 
and concordant for the group if the defect belonged to the same spectrum of CHD, that 
is, group of shunts, conotruncal lesions, left and right heart obstructive lesions, and 
laterality defects/dextrocardia. The overall exact concordance of recurrent CHD is 
reportedly 37%, with a group concordance (within the same spectrum of CHD) of 44%, 
according to an analysis of 6,640 consecutive pregnancies evaluated by fetal 
echocardiography.
92
 This study found that in families where there were two or more 
recurrences, the exact concordance rate was 55%, and these were particularly high for 
isolated AVSDs (80%) and laterality defects (64%).
92
 According to Fesslova et al., 
complete concordance of recurrent CHD was found in 21.2% and a partial concordance 
in additional 20% of cases.
89
Among discordant pairs of lesions, some occur more 
frequently and mainly within the group of septal defects (ASD, VSD, AVSD) or 
between TOF, TGA, and VSD.
89
 Equally, the variability between different types of the 
left ventricular obstructive lesions has been reported in several studies.
94
 
The single-gene causes of familial clustering of nonsyndromic CHD are 
examples that could underlie the strong recurrence risks of the same heart defect 
phenotype (concordant defects).
28
 They may also give rise to different phenotypic 
effects (pleiotropy) in the same family
17
, which could explain the several case studies on 
families with clustering of different heart defects (discordant lesions).
28
 Among other 
hypothesis to explain this situation, such as epigenetic and environmental interactions, 
one should bear in mind of the possibility of maternal and paternal imprinting, in which 
genes behave differently depending upon paternal versus maternal inheritance.
86
 
 Chromosomal and syndromic heart defects play only a small role in recurrent 
heart defects.
28
 Although recurrence risk ratios are strong, very few families experience 





Familiar risk by specific CHD  
 Familial occurrence of AVSD is reported both in the presence of euploidy and 
aneuploidy (trisomy 21), with a rate in siblings about 3-4%,
10




often concordant. In another study, the rate in siblings was 6.5%, all affected cases 
being nonsyndromic. In some families there were reported discordant lesions such as 
VSD, ASD, patent ductus arteriosus, and hypoplastic right ventricle with PS.
95
 Vertical 
transmission found in selected pedigrees suggests an autosomal-dominant mechanism, 
with monogenic or oligogenic inheritance.
89
 Recurrence risk is about 10% for an 
affected parent, higher for mothers (14%) and lower for fathers (1%).
10
 
 Familial recurrence of CHD among patients with nonsyndromic TOF was 
reported of 2–5.5%
10,89
, 2-5% in affected mothers and 1-2% in affected facthers.
10
 An 
etiologic relationship was reported for the conotruncal lesions, PS, and VSD.
94
 
TGA is generally considered to have a sporadic occurrence in families, with a 
total risk of around 3%
89
, and 1-2% in siblings.
10,89
 However, a study showed 
concordant cardiac defects within affected family members with TGA, suggesting that 
this disease is not always sporadic in families and supports monogenic or oligogenic 
inheritance of TGA in certain kindreds.
96
 Another study found recurrent discordant 
lesions, namely VSD and PS.
89
 
Corrected transposition of great arteries (l-TGA) has a total risk of recurrence of 
6.7%
89
 and a recurrence of 5-10% in siblings.
10,89
  
Aortic stenosis (AS) has a total recurrence of 4.3%
89
, a recurrence in siblings of 
2%
10
 and 7.4-20% in offspring when the mother is affected
10,89
 and 5-5.9% when the 
father is affected.
10,89
 CoA has a documented total recurrence of 2.2%
89
 and a 
recurrence among affected mothers of 4-5.9%
10,89
 and among affected fathers of 2-
14.3%.
10,89
 The highest recurrence rate observed in the offspring among affected fathers, 
may be due to the low number of affected parents observed in that study.
89
 HLHS has a 
5% risk of association with BAV in a parent and a sibling recurrence risk between 2 and 
9%.
17
 Obstructive lesions of the left outflow tract have a high degree of heritability and 
are presumed to be due to an altered embryonic blood flow. They may occur in families 
with variable degrees of severity starting with bicuspid aortic valve (BAV), AS, CoA, 
and HLHS suggesting a genetic predisposition to the flow alterations.
95,97
 An autosomal 
recessive transmission has been suggested.
98
 It is reported that up to 20% of the 
asymptomatic first-degree relatives of patients with obstructive left heart lesions may 
have undiagnosed CHD, in particular bicuspid aortic valve (BAV).
99
 These data suggest 
that cardiac screening of relatives of patients with obstructive left heart lesions without 
noncardiac anomalies is justified. This may help prevent sudden, 
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PA and TA have each a recurrence in siblings reported as 1-3%.
10
 Pulmonary 
stenosis is known to be frequently associated with Noonan syndrome and has a total 








VSD has a total recurrence rate between 1.7 and 4.2%
89
, 1.59-3% in siblings, 7-
10% in affected mothers and 2-7% in affected fathers.
10,89
 
Familial ASD is usually due to an autosomal dominant transmission. However, 
the genetics of ASD is considered to be heterogeneous.
100
 The recurrence of ASD is 
reported between 2.5 and 4.1%
10,89
, lower in fetuses from affected siblings (2-3%)
10,89
 
and higher in fetuses from affected mothers and fathers (6% and 1-5%).
10,89
 
Recurrence for the laterality defects has been reported to be between 2 and 
4.75%
89
 and 5-6% in siblings. It was found a concordant recurrence in siblings of 5.3% 
with left isomerism and AVSD, but with different associated intracardiac lesions.
89
 
High relative risk ratio for heterotaxy recurrence among first-degree relatives was 
reported (79.1, 32.9-190).
28
 Out of 22 cases with dextrocardia, either with situs solitus 






 Several environmental factors have been found that might cause CHD. However, 
less information is available regarding the potential adverse effect of modifiable risk 
factors on the fetal heart, which has made it difficult to develop population-based 
strategies targeting CHD development and to assist couples in making lifestyle choices 
to reduce the likelihood of having a child with a CHD. The proportion of CHDs 
potentially preventable through changes in the fetal environment is unknown, but it is 
suggested that the fraction of cases attributable to identifiable and potentially modifiable 
factors may be as high as 30 % for some defects.
12
  
The modifiable risk factors are limited to the periconceptional period, which is 
defined as the 3 months before pregnancy through the third month of pregnancy, 







Two population-based studies merit further mention because they are the source 
for the majority of information regarding risk factors for the development of CHD. The 
Baltimore-Washington Infant Study (BWIS), conducted between 1981 and 1989, was a 
case–control study designed to further characterize the epidemiology of CHD (59, 60). 
The case infants were live-born infants with a CHD from the Baltimore-Washington 
area. During the study period, 4,390 cases and 3,572 control patients were enrolled in 
the study. The National Birth Defects Prevention Study (NBDPS), which began in 1997, 
is designed to identify infants with and without major birth defects and to evaluate 
genetic and environmental factors associated with the occurrence of birth defects (35). 
This ongoing case-control study includes case and control infants from birth defect 
surveillance registries in 10 states (Arkansas, California, Georgia, Iowa, Massachusetts, 
New Jersey, New York, North Carolina, Texas, and Utah). As of December 2009, 
27,812 cases and 10,200 control subjects are included in the database. 
 
Parental age 
Findings have shown that maternal age, both advanced and younger, is 
associated with CHD. Advanced maternal age was found to be a risk factor with an OR 
(95% CI) varying from 1.2 (1.1-1.3) for women with 35 years or older
102
 to 4.0 (1.7-9.2) 
for women with 40 years or older compared with women aged 20-24 years.
103
 
According to Hollier et al. (2000), the additional age-related risk of 
nonchromosomal malformations was approximately 1% in women 35 years of age or 
older.
103
 Advanced maternal age was found to be associated with EA, TGA, ASD, VSD, 
CoA and TOF.
12





 and total anomalous pulmonary venous return (TAPVR).
105
 
A clear steady pattern of increasing relative risk with advancing paternal age 
from 35 years of age onwards was found for heart malformation (OR: 1.2, 1.1-1.4).
106
 A 
matched case-control study performed in Egypt identified an association between 
advanced paternal age and VSDs.
107
 However, given the weak association, paternal age 
appears to play a small role in the etiology of CHD. 
 
Pre-gestational diabetes 
 Pre-gestational diabetes is highly associated with multiple congenital cardiac 
defects (OR varying between 2.2, 1.9-2.6,
108
 and 4.6, 2.9-7.5
109
), including ASD, VSD, 
AVSD, CoA, double-outlet right ventricle (DORV), pulmonary atresia (PA), TAPVR, 
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TGA, TOF and truncus arteriosus.
12
 It is hypothesized that pre-gestational diabetes 
inhibits expression of Pax3 in neuroepithelium through hyperglycemia-
induced oxidative stress. This gene is required for cardiac neural crest 
(CNC) migration to the heart and for outflow tract septation. Therefore, its inhibition 
can lead to outflow tract defects.
110
 It appears to induce malformation before the seventh 
weak of gestation, during the critical period of organogenesis, and is considered as an 
independent risk factor for mortality among infants with CHD.
12
 The prevalence of birth 
defects among diabetic women with good glycemic control is similar to that in general 
population, so it appears that euglycemia reduces the risk of birth defects.
111
 However, 
achieving and maintaining euglycemia in the early pregnancy remains a challenge 
because many women with diabetes do not plan their pregnancies and do not achieve 
adequate glycemic control before conception. Therefore, glycemic control has been 
proposed as a prevention strategy for birth defects, but as the prevalence of diabetes and 
risk factors for diabetes continues to rise, it appears that this may not be effective only 
by itself.
12
 The associations between CHD with Gestational Diabetes Mellitus (GDM) 
were weaker and generally limited to offspring of women with a prepregnancy BMI 
≥25.0 kg/m
2
, which is consistent with the hypothesis that associations of birth defects 





 Maternal febrile illness during the first trimester of pregnancy has been 
investigated for its role in the development of CHDs. Nevertheless, it is difficult to 
evaluate febrile illness as a risk factor, due to its complex definition. It can be caused by 
respiratory infections, influenza, urinary infections and so on. Even limiting the 
definition of fever to the presence of these etiologies has not identified consistent 
associations, suggesting the need for further investigations. It was found in the 
Hungarian population an association between acute inflammatory pelvic disease (APID) 
in the second or third month of pregnancy and CHD (OR: 2.6, 1.2-5.4), particularly 
secundum ASD, with a 4.2 fold increase, but more studies are needed to support this 
finding.
112
 Maternal fever or influenza were found to be associated with a significantly 
increased risk of having an offspring with a right-sided obstructive heart defect, 
especially TA and PA with intact ventricular septum, and AVSD in patients with Down 
Syndrome.
113




symptomatic treatment of febrile illness and influenza in pregnant women might have 
beneficial effects on the developing fetus.
113
  
 The possible mechanisms underlying the associations observed between 
maternal fever or influenza and specific types of CHD are unclear. Associations 
between maternal urinary tract infections and cardiac defects were found, namely left 
ventricular outflow tract obstructive defects and AVSDs, which remained among 




 Maternal rubella infection during the first trimester of pregnancy commonly 
results in multiple anomalies, including PDA, VSD, ASD, PS and TOF. Infections by 
cytomegalovirus, herpesvirus, and coxsackievirus B are suspected to be teratogenic if 
they occur in early pregnancy, but if they occur later in pregnancy they may cause 
myocarditis. Human immunodeficiency virus infection (in illicit drug users) has been 




Untreated maternal phenylketonuria is associated with a 6-fold-increased risk of 
heart defects.
115,116
 The most frequent defects are TOF, VSDs, PDA and single 
ventricle. Fortunately, with strict diet control before conception and during pregnancy, 





 Folate is essential to the cardiovascular development. Reduced levels of folate or 
vitamin B12 results in hyperhomocysteinemia. Homocysteine causes cellular oxidative 
stress through the production of reactive oxygen species and binds to nitric oxide or 
leads to the accumulation of its precursor, a potent inhibitor of biologic 
transmethylations, Three studies demonstrated an increased risk of CHD in infants born 
to mothers with high homocysteine levels (OR varying between 1.5 and 3.5), but their 





 It was identified an approximate twofold increased risk of CHDs among infants 
born to mothers with hypertension, but no association by defect was found, and it is still 
being investigated whether the underlying hypertension or the antihypertensive drugs is 
38 
 
the basis for the increased risk. Nonetheless, it is suggested that the apparent 
increased risk of cardiac malformations is more likely to be caused by the underlying 
hypertension (OR 1.4, 1.3-1.5) rather than the antihypertensives used during the first 





 The prevalence of overweight and obesity is increasing at an alarming rate. 
Increased prepregnancy weight is associated with a slightly increased risk of CHDs. 
There was a highly significant trend of increasing risk for CHDs with 
increasing maternal obesity: Body Mass Index (BMI) 30-34.9 (OR 1.16, 1.07-1.25); 
BMI 35-39.9 (OR 1.25, 1.13-1.39); BMI ≥ 40 (OR 1.49, 1.32-1.69). Overweight (BMI 
between 25 and 30 kg/m
2
) was not associated as a risk factor (OR: 1.00, 0.94-1.06), but 
it is not conclusive, so further studies are needed to confirm this conclusion.
118
 The 
association was greatest for left and right ventricular outflow tract defects and no 
association was found for conotruncal defects (OR 1.04, 0.82-1.33)
119
. Each category of 
BMI was associated with different CHDs. Overweight mothers were more likely to have 
an infant with CoA
120
, although the sample size of the study was very limited. Obese 
mothers were more likely to have an infant with ASD, AS, HLHS, PVS or truncus 
arteriosus.
118
 A BMI greater than 40 kg/m
2





 History of infertility and use of assisted reproductive techniques (ART), which 
include inductors of ovulation (IO), in vitro fertilization (IVF) and intracytoplasmic 
sperm injection (ICSI), have been identified as having a 1.3 fold increased risk of CHDs 
of any type and 1.4 fold increased risk of CHD without chromosomal abnormalities.
121
 
 In contrast, it was not found any statistically significant association between IO 
and CHD. The cardiac defects most reported are ASD, AS, CoA, TOF and VSD.
121
 It 
was found an association between clomiphene citrate use in CoA, AS and VSD as a 
subfertility treatment in the period from 2 months before conception through the first 
month of pregnancy.
122
 Although the mechanism is not clear, couples considering ART 
should be informed of all potential risks and benefits.  
 Multiparous women have a greater risk than mothers of infants without 
structural heart defects.
12




having an infant with CHD, however when stratified by defect, significant associations 





 Low maternal and paternal socioocupational status was associated with infant 
CHDs in an investigation of more than 81,000 births in Denmark (OR: 1.4-1.6).
124
 A 3.4 
fold risk was shown as well in mothers with low socioeconomical status (SES) in a 
small case-control study in Lithuania.
125
 A large multicentered case-control study was 
conducted in 1,841 cases and 2,551 nonmalformed liverborn controls delivered in 1997-
2000. Particular characteristics, such as unemployed mother or father, low education of 
either parent, low household income and maternal occupation were associated with 
increased risks of TGA and TOF. However, no marker of socioeconomic status was 
statistically significant.
126
 This study revealed consistently increased risks of selected 
birth defects in association with household SES index but not individual SES measures.  
 
Stress 
 One potential mechanism whereby stressful life events may lead to birth defects 
is through increased production of maternal corticotrophin-releasing hormone and 
corticosteroids during pregnancy. High levels of these hormones are associated with 
hyerinsulinemia, insulin resistance and teratogenicity. Stress can result as well in 
increased catecholamine production, which leads to decreased uterine blood flow and 
increased fetal hypoxia.
12
 A case-control study in China identified a threefold greater 
risk of CHDs
127
 and an association with TGA was identified.
128
 The maternal 
periconceptional stressful life events, social support, and the two factors in combination 
were at most modestly, if at all, associated with risks of conotruncal heart defects. 
However, social support was associated with reduced risks, most notably for TGA.
129
   
 
Maternal medications 
 Thalidomide is known to be a cardiac teratogen and therefore contraindicated 
during pregnancy and among women planning a pregnancy. Thalidomide embryopathy 
includes CHD from VSDs and ASDs to complex conotruncal defects.
130
 No safe dose of 
thalidomide treatment during the critical period of gestation has been established, and 
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cases of thalidomide embryopathy have been described after maternal ingestion of as 
little as one 50-mg capsule during this time. 
 Maternal intake of isotretinoin has been shown to cause congenital cardiac 
defects in addition to other malformations. Characteristic features of isotretinoin 
embryopathy include central nervous system malformations, micrognathia, cleft palate, 
thymic and eye anomalies, and cardiac and great vessel defects. The frequency of 
congenital anomalies does not appear to be increased among children of women who 
discontinue therapy before conception. These medications are contraindicated during 
pregnancy and among women planning a pregnancy.
115
 
The use of antidepressants during the periconceptional period , such as selective 
serotonin-reuptake inhibitors (SSRI’s), serotonin-epinephrine reuptake inhibitors 
(SNRI’s) and tryciclic antidepressants (TCAs), is associated with CHD 
development.
131,132,133
 When evaluated by defect, ASD (paroxetine
134
 and venlafaxine 
use 
132
), VSD (fluoxetine use)
131
 and CoA (venlafaxine use)
132
 remained significantly 
associated. However, given the weak associations noted, additional investigations are 
needed.  
Antihypertensives were associated with a two- to threefold increase in the risk of 
CHD.
135,136
 However, more recent studies have not reported significant associations
117
 
and conflicting results have been reported when examining specific types of 
antihypertensive medications, such as beta-blockers and ACE inhibitors.
117,135,136
 
According to the NBDPS database, secundum ASD, CoA, Ebstein´s anomaly and PVS 
were found associated with first trimester use; secundum ASD, perimembranous VSD 
and PVS were associated to antihypertensive treatment after the first trimester.
135
 A 
modest nonsignificant elevation in the risk for all CHDs was observed not only to first-
trimester ACE inhibitor use, but for antiadrenergic, beta-blockers and, in a lesser extent, 
to diuretics as well.
135
 Calcium-channel blockers were not associated with increased 
risk.
135
 These findings contrast with those reported by Cooper et al.
137
 In that study, 
first-trimester ACE inhibitor use was associated with risk of CHDs (OR: 3.7, 1.9-7.3), 
whereas use of other medication classes was not, leading these authors to attribute their 
findings to ACE inhibitor exposure and not to the underlying hypertension.  
Anti-infection medications, including antibiotics and antifungals, are commonly 
prescribed during the periconceptional period of pregnancy. Two large studies using the 
NBDPS and the Swedish Medical Birth Register were unable to identify a significant 






 However, increased risk of CHD
139
, CoA and HLHS
138
  have been reported 
for mothers using sulfonamide medications (folic acid antagonists). These increased 
risks also were reduced if the mother concomitantly took folic acid supplementation.
140
 
The BWIS identified a significant association between metronidazole use and the 






 were found associated 
with metronidazole use. Examination of the NBDPS data did not identify an increased 
risk among mothers who reported using metronidazole.
144
  
No consistent associations between maternal use of any type of NSAID and the 
development of CHDs have been reported.
145,146
 Various types of NSAIDs also have 
been evaluated for their role in CHD formation. Although aspirin is not significantly 
associated with CHDs as a group, maternal use of aspirin is reported to be associated 
with interrupted aortic arch (IAA).
147
 The BWIS data showed an association between 
ibuprofen use and an increased risk of CHDs.
141
 Stratification by defect identified a 
significant association between ibuprofen and Down syndrome associated with AVSD, 
DORV, and TGA.
142
 An association between maternal use of naproxen and CHDs 
overall has been demonstrated, namely PVS.
145,148
 
Amphetamines have been associated with VSD, PDA, ASD and TGA.
78
 
Anticonvulsivants are suspecting of causing CHD. Specifically, phenytoin has been 
associated with PVS, AS, CoA and PDA.
78
 Valproic acid may be associated with 
various heart defects such as ASD, VSD, AS, PA with intact ventricular septum, and 
CoA.
154
 Trimethadione has been associated with TGA, TOF and HLHS
78
 and lithium 
has been associated with Ebstein’s anomaly.
152
 Retinoic acid may cause conotruncal 
anomalies, namelyTGA, as observed in murine and chick embryo hearts.
153
 Other 




Multivitamin supplements containing folic acid may reduce the risk for some 
types of CHD, similar to the known risk reduction of neural tube defects seen with folic 
acid. The use of periconceptional folic acid supplements was related to approximately 







significant risk reduction. Reduction in risk was present when the multivitamin 
supplementation was used at about the time of conception or early in the first month of 
pregnancy but not when it was started during the second or third months of pregnancy, 
suggesting that the underlying mechanism of folate is most effective during the critical 
period of cardiac development.
12 
The exact mechanism of folic acid’s protective effect 
42 
 
has yet to be elucidated. One hypothesis is that folic acid prevents congenital defects by 
stimulating cellular methylation reactions. Folic acid-deficient rats have been reported 
to produce offspring with VSDs and defects of the outflow tract and great vessels, 




Parental nontherapeutic drug exposures 
 Alcohol may have an impact on heart development through its contribution to 
impaired conversion of retinol to retinoic acid, antagonism of the N-methyl-D-aspartate 
(NMDA) receptor, compromised nutritional status, and vascular disruptive events.
12
 
Conflicting results have been reported for maternal alcohol consumption during the 
periconceptional period. A majority of studies have not reported a significant 
association between maternal alcohol use and CHDs. However, a case-control study 
reported a threefold risk for CHDs among mothers who reported periconceptional 
alcohol use.
155







majority of studies evaluating the adverse outcomes related to alcohol have focused on 
maternal consumption, but paternal consumption also has been investigated for its role 




 Caffeine is known to cross the placenta, so concerns have led to inform pregnant 
women to limit their caffeine intake.
115
 Using data from the NBDPS, the consumption 
of coffee, tea, soda, and chocolate was examined for an association with select CHDs, 
and no evidence for a teratogenic effect of caffeine was identified.
159
 
 Various studies, including BWIS database, did not identify a significant 
association between maternal periconceptional cigarette smoking and the development 
of CHDs as a group.
160
 However, a study using the NBDPS database did identify an 
increased risk for the development of CHDs among mothers who reported use of 
cigarettes (OR: 1.2, 1.1-1.4).
161
 A population-based study showed as well that offspring 
of mothers reporting cigarette use in the first trimester of pregnancy were more likely to 
be born with a CHD (OR 1.16, 1.08-1.24).
163
  Subtypes at increased risk are: AVSD 





, truncus arteriosus (OR: 1.90, 1.04-3.45), and levo-transposition of the 
great arteries (l-TGA) (OR: 1.79, 1.04-3.10).
160
 The association was stronger with 
increasing number of daily cigarettes, namely more than ten cigarettes daily, and among 
older (35+ years) mothers compared with younger mothers.
163




an association between maternal passive smoke exposure and AVSDs.
162
 Few studies 
have evaluated the effect of paternal smoking, and the results have been conflicting, 
similar to the results for maternal smoking. The BWIS did not identify a significant 
association between paternal cigarette smoking and CHDs as a group or any CHD 
subtype.
141
 A study performed in Italy demonstrated an increased risk of CHDs as a 
group among fathers who reported smoking (OR 1.7, 1.1-2.6).
164
 The mechanisms by 
which cigarette smoke or the chemical compounds contained within the smoke might 
result in CHDs remain to be elucidated. 
 Data from the BWIS showed an association between maternal and paternal 
cocaine use and CHDs (OR: 1.6, 1.1-2.3; OR: 1.7, 1.3-2.2, respectively).
141
 Stratified by 
defect, VSD, TA, ASD and AVSD were associated with cocaine use, remaining AVSD 
as the only not associated with paternal cocaine use.
142
 Cocaine may exert direct toxic 
effects on fetal myocytes. Although maternal marijuana use is not reported to be 
associated with CHDs as a group, findings have demonstrated its association with 
VSDs
158
 and Ebstein’s anomaly
142
. However, data from the BWIS have demonstrated 
that paternal marijuana is associated with an increased risk for the development of any 
type of CHDs (OR: 1.2, 1.1-1.4)
141





these studies did demonstrate positive associations, it should be noted that the number 
of individuals who reported illicit drug use was extremely small, making interpretation 
of these results limited. 
 Studies have examined the effects of maternal environmental air pollutant 
exposure and subsequent CHD development and there was little or no association.
166,167
 
 Exposure to occupational chemicals, especially during the periconceptional 
period, influences the reproductive system in both men and women and may lead to 
adverse health effects in children. Plausible mechanisms include reduced sperm quality, 
disrupted epigenetic programming during maturation of sperm cells, impaired 
maturation of oocytes, and impaired embryogenesis.
168
 However, the relationship 
between chemical exposure and CHDs is not clear.
169
 Associations between maternal 
exposure to organic solvents during the periconceptional period were observed for CoA, 
HLHS, and TGA.
142
 Maternal exposure to cyanide or heavy metals is associated with 
CHDs (OR: 2.2, 1.3-3.9; OR: 1.5, 1.1-2.3, respectively).
170
 A study showed an 
association between paternal exposure to phthalates or alkylphenolic compounds during 
the periconceptional period and an increased risk of infant CHDs in general (OR: 1.7, 
1.1-2.5; OR: 1.8, 1.1-3.0, respectively).
171
 In this study, paternal exposure to phthalates 
44 
 
was associated with VSDs, exposure to polychlorinated compounds was associated with 
AVSDs, and exposure to alkylphenolic compounds was associated with CoA.
171
 
Chemical exposures were difficult to define in these studies, and the associations 
identified were weak, suggesting that these results need to be replicated for a definition 
of the true risk they represent. 
 Multiple studies have examined the relationship between CHDs and maternal 
exposure to contaminated water with trichloroethylene and dichloroethylene. 
Trichloroethylene, a hydrocarbon solvent used as a metal degreasing agent, is an 
intermediate product in the production of polyvinyl chloride.
172
 It also has uses as an 
anesthetic, antiseptic, solvent for dry cleaning, and coffee decaffeination. 
Dichloroethylene is a chemical used for synthesis of polyvinyl chloride and plastic 
packaging. Gestational dichloroethylene exposure has been demonstrated to result in a 
significant proportion of CHD (OR: 2.8, 1-.3-5.9).
173,174
 
 A six-fold increased risk of CHD in infants born to mothers older than 38 years 
exposed to trichloroethylene compared with those born to nonexposed younger mothers 
was identified (OR: 6.2, 2.6-14.5).
175
 However, two large reviews have reported no 




 Significant associations between multiple risk factors and CHDs have been 
identified. Studies investigating a majority of these risk factors have yielded conflicting 
results, suggesting that additional investigations need to be performed. Most of the 
studies have had small samples due to the rarity of specific types of CHDs. It is also 
difficult to perform precise measurements of some exposures, such as occupational and 
environmental exposures. It is interesting to note that a large proportion of the risk 
factors were observed to be associated with a variety of CHDs, suggesting that chance 
associations may have been observed as opposed to true associations. Mechanisms for 
these associations are difficult to define because multiple categories of defects were 
found to be associated with a specific risk factor, further implying that these 




Specific congenital heart defects 
 In the following section, the majority of specific congenital heart defects will be 




Figure 2. Anatomic types of atrial septal defects (ASDs) viewed with the right atrial wall 
removed. IVC, inferior vena cava; SVC, superior vena cava.78  
environmental factors associated and phenotypes. Management of CHDs remains 
beyond the scope of this review. 
 
Left-to-Right Shunt lesions 
Atrial septal defect (ASD) 
Atrial septal defect (ASD) occurs as an isolated anomaly in 5 % to 10% of all 
congenital heart defects, may be first encountered in the adult and occurs more 
frequently in females (male/female ratio of 1:2). About 30% to 50% of children with 
CHDs have an ASD as part of the cardiac defect.
78
 There are four types of ASD: Ostium 
secundum defect, ostium primum defect, sinus venous defect and coronary sinus ASD, a 
very rare defect (Figure 2). Patent foramen ovale (PFO) does not ordinarily produce 
intracardiac shunts; it is considered a common normal variant, which lacks total 
obliteration of the foramen ovale after birth. 
 Environmental factors for ASD include advanced maternal age (OR: 2.5, 1.5-
4.1)
105
, pre-gestational diabetes (OR varying from 2.3, 1.8-2.8 
108
, to 8.5, 4.4-16.4 
109), 
gestational diabetes (OR: 2.2, 1.5-3.2)
109
, prepregnancy obesity (OR: 1.2, 1.1-1.4)
118
, 
infertility/ART (OR: 3.4, 1.6-6.2)
176





 and venlafaxine use (OR: 2.9, 1.2-6.9)
132
, antihypertensive use during 







alcohol (OR: 2.0, 1.1-3.4)
156
, cigarette use (OR: 2.0, 1.5-2.6)
161




Patients with ASD are usually asymptomatic in early life although there may be 
some physical underdevelopment (relatively slender body build) and an increased 
tendency for respiratory infections; Cardiorespiratory symptoms occur in many older 
46 
 
patients. During the fifth and sixth decades, the incidence of progressive symptoms, 
often leading to severe disability, increases substantially. If a large defect is left 
untreated, a significant number of patients beyond the third and fourth decades of life 
develop atrial arrhythmias, pulmonary arterial hypertension and right heart failure. 
Patients with sinus venosus or ostium secundum ASDs rarely die before the fifth 
decade.
7
. The defect may decrease in size or even close spontaneously in some patients.  
 
Ventricular septal defect (VSD) 
VSD is the most common of all cardiac birth defects and accounts for 15% to 
20% of all such defects, either as an isolated defect or as a component of a combination 
of anomalies, not including those occurring as part of cyanotic CHDs. The VSD is 
usually single and situated in the membranous or midmuscular portion of the septum, 
but it can occur in other regions of the septum. Only small- or moderate-size VSDs are 
seen initially in adulthood, as most patients with an isolated large VSD come to medical 
or surgical attention early in life.
7
  
Environmental risk factors for VSD include advanced maternal age (OR: 2.5, 
1.8-3.5)
105
, advanced paternal age (OR: 1.7, 1.3-2.3) based on a study conducted in the 
children’s hospitals of Alexandria, Egypt
107
, pre-gestational diabetes (OR varying 
between 1.5, 1.2-1.8 
108
, and 2.9, 1.3-6.6 
109
), infertility and ART (OR: 1.4, 1.1-1.8)
121
, 
clomiphene citrate use as a subfertility treatment (OR: 1.6, 1.1-2.4)
122
, nulliparity (OR: 
1.4, 1.2-1.6)
123
, fluoxetine (OR: 1.7, 1.1-2.4)
131
, antihypertensive treatment after the 
first trimester for perimembranous VSDs (OR: 2.3, 1.2-4.6)
135
, metronidazole (OR: 1.6, 
1.2-2.3)
143





alcohol use (OR: 3.1, 1.2-8.2)
158
, paternal alcohol use (OR: 4.0, 1.6-9.9)
158
, cigarette use 
(OR: 1.3, 1.1-1.7)
161
, maternal cocaine use (OR: 2.9, 1.7-4.8)
142
, paternal cocaine use 
(OR: 2.3, 1.6-3.3)
142
, maternal marijuana use (OR: 2.4, 1.4-3.9)
158
, paternal marijuana 
use (OR: 2.2, 1.1-4.4)
165
 and paternal exposure to phthalates (OR: 2.8, 1.4-5.9).
171
 VSDs 
exhibited significant risk reduction with folic acid use (OR: 0.8, 0.8-0.9).
143
 
The defects vary in size, ranging from tiny defects without hemodynamic 
significance which can close spontaneously to large defects with accompanying CHF, 







Atrioventricular septal defect (AVSD) 
There are two forms of AVSD: complete and partial. Complete AVSD (also 
called complete endocardial cushion defect or AV communis) occurs in 2% of all 
congenital heart defects. Of patients with complete AVSD, about 70% are children with 
Down syndrome. Of children with Down syndrome, about 40% have congenital heart 
defects and 50% of the defects are AVSD. AVSD is also a component of heart defects 
in asplenia and polysplenia syndromes. It consists in an ostium primum ASD, inlet VSD 
and clefts in the anterior mitral valve and the septal leaflet of the tricuspid valve 
(forming the common AV valve). Partial AVSD (also called partial endocardial cushion 
defect or ostium primum ASD) occurs in 1% to 2% of all congenital heart defects and 




Risk factors for AVSD include pre-gestational diabetes (OR varying from 2.2, 
1.2-4.0
108
, to 12.4, 3.7-41.5
109
), maternal urinary tract infections, although not 
conclusive yet (OR: 2.3, 1.1-4.7)
114
 and maternal fever (OR: 1.9, 1.1-3.4) and influenza 
(OR: 1.7, 1.04-2.6) in infants with Down Syndrome.
113
 It is unclear why AVSD in 
patients with Down syndrome may be associated with fever and influenza and AVSD in 
patients without Down syndrome is not. This finding may represent an important gene–
environment interaction that warrants further investigation, or the observed association 
may be only incidental.
113
 Other environmental risk factors are: ibuprofen associated 
with Down Syndrome-AVSD (OR: 2.4, 1.1-4.2)
142
, cigarette use (OR: 1.5, 1.1-2.1) with 
the strongest association in mothers who smoked more than 25 cigarettes/day
162
, 
maternal passive smoke exposure (OR: 1.5, 1.1-2.1)
162
, cocaine use (OR: 3.5, 1.1-
11.4)
142
 and paternal exposure to polychlorinated compounds (OR: 4.2, 1.2-14.4).
171
 
Abnormalities seen in complete AVSD may result in interatrial and 
interventricular shunts, LV-to-RA shunt, and AV valve regurgitation. Clinical 
manifestations include failure to thrive, repeated respiratory infections, and signs of 
CHF. For patients with complete AVSD, heart failure occurs 1 to 2 months after birth 
and recurrent pneumonia is common. Without surgical intervention, most patients die 
by the age of 2 to 3 years. In the latter half of the first year of life, the survivors begin to 
develop pulmonary vascular obstructive disease. These survivors usually die in late 
childhood or as young adults. Infants with Down syndrome are particularly susceptible 
to the early development of pulmonary vascular obstructive disease during infancy. As a 





Pulmonary outflow obstruction 
Pulmonary valve stenosis (PVS) 
 Obstruction to RV outflow may be localized to the supravalvular, valvular, or 
subvalvular levels or occur at a combination of these sites. Multiple sites of narrowing 
of the peripheral pulmonary arteries are a feature of rubella embryopathy and may occur 
with both the familial and sporadic forms of supravalvular aortic stenosis. Valvular 
pulmonic stenosis is the most common form of isolated RV obstruction.
7
  
Environmental risk factors include prepregnancy obesity (OR: 1.3, 1.1-1.6)
118
, 
antihypertensive treatment during the first trimester of pregnancy (OR: 2.6, 1.3-5.4)
135
 
or after first trimester (OR: 2.4, 1.1-5.4) 
135





and cigarette use (OR: 2.3, 1.1-4.8).
161
 
Patients with mild PVS are generally asymptomatic and demonstrate little or no 
progression in the severity of obstruction with age. In patients with more significant 
stenosis, the severity may increase with time. Symptoms vary with the degree of 
obstruction. Fatigue, dyspnea, RV failure, and syncope may limit the activity of older 
patients, in whom moderate or severe obstruction may prevent an augmentation of 




Pulmonary atresia (PA) 
 Pulmonary atresia with intact ventricular septum accounts for fewer than 1% of 
all congenital heart defects.
78
 A history of severe cyanosis since birth is present.  
 Risk factors for PA include pre-gestational diabetes (OR: 7.2, 1.6-31.4)
12
 and 
maternal influenza (OR: 2.7, 1.2-6.3)
113
. 
 Without appropriate management (which includes PGE1 infusion and surgery), 
the prognosis is exceedingly poor. About 50% of these patients die by the end of the 




Aortic outflow obstruction 
 Malformations that cause obstruction to LV outflow include AS, discrete 
subaortic stenosis, SVAS, BAV, CoA and HLHS. Obstructive left heart lesions 
generally have noticeably higher recurrence risks in siblings of unaffected parents 
and/or offspring of affected parents compared with other types of CHD.
177
 The 






Aortic valve stenosis (AS) 
Aortic stenosis (AS) occurs in about one-fourth of all patients with chronic 




Risk factors for congenital AVS include pre-gestational diabetes (OR: 5.0, 1.1-
22.9)
109
, prepregnancy obesity (OR: 2.2, 1.2-4.0)
118
, infertility and clomiphene citrate 
use as a subfertility treatment (OR: 2.6, 1.2-5.3)
122
. 
AS is rarely of clinical importance until the valve orifice has narrowed to 
approximately 1 cm
2
. Even severe AS may exist for many years without producing any 
symptoms because of the ability of the hypertrophied LV to generate the elevated 
intraventricular pressures required to maintain a normal stroke volume. Once symptoms 
occur, valve replacement is indicated. Exertional dyspnea, angina pectoris, and syncope 
are the three cardinal symptoms. Often, there is a history of insidious progression of 
fatigue and dyspnea associated with gradual curtailment of activities and reduced effort 
tolerance.
7
  Diagnosis is made by echocardiography, which reveals the morphology of 




Supravalvular aortic stenosis 
 This is a localized or diffuse narrowing of the ascending aorta originating just 
above the level of the coronary arteries at the superior margin of the sinuses of 
Valsalva.
7
 It is the most commonly associated cardiac defect in WilIiams-Beuren 





Bicuspid aortic valve (BAV) 
 Bicuspid aortic valve is the most common congenital heart valve defect, 
occurring in 0.5–1.4% of the population, and is more common in males than in females 
(2-4:1). The congenital bicuspid aortic valve may initially be functionally normal and 
may go undetected in early life.
7
  
 The inheritance pattern appears to be autosomal dominant with incomplete 
penetrance, although some have questioned an X-linked component as suggested by the 
prevalence of BAV disease among patients with Turner’s syndrome.
29
 The prevalence 
of BAV disease among first-degree relatives of an affected individual is approximately 
24%.
17
 It is a frequent finding in parents of children with other left-sided obstructive 
50 
 
defects and there is a 19.3% prevalence of cardiac anomalies in first-degree relatives 
with BAV.
17
 A single gene defect to explain the majority of cases has not been 
identified, although a mutation in the NOTCH1 gene has been described in some 
families.
7
   
 
Coarctation of the aorta (CoA) 
 Narrowing or constriction of the lumen of the aorta may occur anywhere along 
its length but is most common distal to the origin of the left subclavian artery near the 
insertion of the ligamentum arteriosum. Coarctation occurs in around 7% of patients 
with CHD, is more common in males than females, and is particularly frequent in 
patients with Turner syndrome.
7
 
 Environmental risk factors for CoA include advanced maternal age (OR: 1.5, 
1.1-2.2)
102
, pre-gestational diabetes (OR: 1.9, 1.2-3.1)
108
, prepregnancy overweight 
(OR: 3.9, 1.1-13.8)
120
, infertility, ART and clomiphene citrate use (OR: 2.3, 1.4-3.8)
122
, 
venlafaxine (OR: 4.5, 1.4-12.5)
132
, antihypertensive treatment during the first trimester 
(OR: 3.0, 1.3-6.6)
135







organic solvents (OR: 3.2, 1.3-7.9)
142
 and paternal exposure to alkylphenolic 
compounds (OR: 3.9, 1.2-12.7).
171
 
Most children and young adults with isolated, discrete coarctation are 
asymptomatic. Headache, epistaxis, chest pressure, and claudication with exercise may 
occur, and attention is usually directed to the cardiovascular system when a heart 
murmur or hypertension in the upper extremities and absence, marked diminution, or 
delayed pulsations in the femoral arteries are detected on physical examination.  
The chief hazards of proximal aortic severe hypertension include cerebral 
aneurysms and hemorrhage, aortic dissection and rupture, premature coronary 
arteriosclerosis, aortic valve failure, and LV failure; infective endarteritis may occur on 
the coarctation site or endocarditis may settle on an associated bicuspid aortic valve, 




Hypoplastic Left Heart Syndrome (HLHS) 
 HLHS occurs in 1% of all congenital heart defects. HLHS includes a group of 
closely related anomalies characterized by hypoplasia of the LV and encompasses 
atresia or critical stenosis of the aortic or mitral valves, or both, and hypoplasia of the 













 and organic solvents (OR: 3.4, 1.6-6.9).
142
 
 Echocardiography findings are diagnostic and usually obviate the need for 
cardiac catheterization and angiocardiography. Pulmonary edema and CHF develop in 
the first week of life. Circulatory shock and progressive hypoxemia and acidosis result 
in death, usually in the first month of life.
78
 However, with the proper medical and 





 General considerations about heterotaxy syndrome can be seen above. Among 
genes associated with these defects, the X-linked inheritance through mutations in ZIC3 
(chromosome Xq26.2) is most reported. Maternal age <20 years was found to be a risk 





Tetralogy of Fallot (TOF) 
 The four components of the tetralogy of Fallot are malaligned VSD, obstruction 
to RV outflow, aortic override of the VSD, and RV hypertrophy due to the RV's 
response to aortic pressure via the large VSD.  
 Risk factors for TOF include advanced maternal age (OR: 2.2, 1.4-3.3)
105
, pre-
gestational diabetes (OR: 4.9, 2.2-11.0)
109
, gestational diabetes (OR: 1.8, 1.1-2.9)
109
, 
infertility/ART (OR: 3.6, 1.9-6.9)
142





, trimethadione, progesterone and estrogen use
78




The severity of RV outflow obstruction determines the clinical presentation. The 
severity of hypoplasia of the RV outflow tract varies from mild to complete (pulmonary 
atresia). Pulmonary valve stenosis and supravalvular and peripheral pulmonary arterial 
obstruction may coexist. When the RV outflow obstruction is severe, pulmonary blood 
flow is reduced markedly, and a large volume of desaturated systemic venous blood 
shunts right-to-left across the VSD. Severe cyanosis and erythrocytosis occur, and 
symptoms of systemic hypoxemia are prominent. In many infants and children, the 
obstruction is mild but progressive. 
52 
 
 For a variety of reasons, only a few adults with tetralogy of Fallot have not had 
some form of previous surgical intervention. Reoperation in adults is most commonly 
for severe pulmonary regurgitation or pulmonary stenosis. Long-term concerns about 
ventricular function persist. Ventricular and atrial arrhythmias occur, respectively, in 
15% and 25% of adults and may require medical treatment, electrophysiologic study 
and ablation, defibrillator placement, or transcatheter or surgical intervention, usually 
including pulmonary valve replacement.  
 
Truncus arteriosus 
 Persistent truncus arteriosus occurs in less than 1% of all congenital heart 
defects. Only a single arterial trunk with a truncal valve leaves the heart and gives rise 
to the pulmonary, systemic, and coronary circulations. A large perimembranous, 
infundibular VSD is present directly below the truncus. The truncal valve may be 
bicuspid, tricuspid, or quadricuspid, and it is often incompetent.
78
 
 Risk factors for truncus arteriosus include pre-gestational diabetes (OR: 2.8, 1.2-
6.9)
108
, pre-pregnancy obesity (OR 6.3; 1.6-24.8)
12




 Most infants present with CHF during the first 2 weeks; 85% of untreated 
children die by 1 year of age. Death occurs around the third decade of life.  
 Because of the frequent association of DiGeorge syndrome, supplementation of 
calcium and magnesium may be indicated. Only irradiated blood product should be used 
for an urgent surgery (because of insufficient time for evaluation of immune status 
accurately). Because of the thymus-based immune deficiency, treatment and 
prophylaxis against pneumococcal and streptococcal infections are important. 




Transposition of the great arteries (TGA) 
 This condition is commonly called dextro-transposition of the great arteries. The 
aorta arises rightward anteriorly from the RV, and the pulmonary artery emerges 
leftward and posteriorly from the LV, which results in two separate parallel circulations; 
some communication between them must exist after birth to sustain life. Most patients 
have an ASD, two-thirds have a patent ductus arteriosus, and about one-third have an 
associated VSD. TGA is more common in males and accounts for approximately 10% 
of cyanotic heart disease.
7




Environmental risk factors for TGA include advanced maternal age (OR: 1.7, 
1.1-2.5)
102
, pre-gestational diabetes (OR varying from 2.0, 1.2-3.2
108
, to 3.3, 1.1-
10.1
109
), low socioeconomical status
126
, maternal periconceptional stressful life events 
(most modestly, if at all, associated)
129
, ibuprofen (OR: 2.5, 1.2-4.9)
142
, amphetamines, 
trimethadione, progesterone and estrogen use
78
, alcohol use (OR: 1.9, 1.1-3.2)
157
, 
cigarette use relatively to levo-transposition of the great arteries (l-TGA) (OR: 1.79, 
1.04-3.10)
160
 and organic solvents (OR: 3.4, 1.5-7.5).
142





 were associated with reduced risks .  





Double-outlet right ventricle (DORV) 
 DORV occurs in less than 1% of all congenital heart defects. DORV occurs 
frequently in patients with heterotaxy in association with other complex cardiac defects. 
Both the aorta and the PA arise from the RV. The only outlet from the LV is a large 
VSD. Infants  without pulmonary stenosis (PS) can develop CHF and later pulmonary 
vascular obstructive disease if left untreated. When PS is present, complications 




Risk factors for DORV include pre-gestational diabetes (OR: 12.3, 2.8-55.2)
12
, 
prepregnancy severe obesity (OR: 2.5, 1.1-5.8)
118
 and ibuprofen (OR: 3.6, 1.1-12.2).
142
 
Surgical treatment is necessary, followed by a long-term, regular follow-up at 6- 




Tricuspid atresia (TA) 
This malformation is characterized by atresia of the tricuspid valve, an interatrial 
communication, and frequently, hypoplasia of the RV and pulmonary artery. The 
clinical picture is usually dominated by severe cyanosis due to obligatory mixture of 
systemic and pulmonary venous blood in the LV.
7
 
Environmental risk factors for TA include maternal age <20 years (OR: 2.6; 1.4-
5.1)
104
, maternal fever (OR: 7.5, 2.6-21.8) and influenza (OR: 6.0, 2.4-15.4)
113
, paternal 
cocaine use (OR: 4.8, 1.6-14.0)
142
 and paternal marijuana use (OR: 2.7, 1.3-5.8).
142
 
Atrial septostomy and palliative operations to increase pulmonary blood flow, 
often by anastomosis of a systemic artery or vein to a pulmonary artery, may allow 
54 
 
survival to the second or third decade. A Fontan atriopulmonary or total cavopulmonary 
connection may then allow functional correction in patients with normal or low 




Ebstein’s anomaly (EA) 
 Ebstein's anomaly of the tricuspid valve occurs in less than 1% of all congenital 
heart defects. This anomaly is characterized by a downward displacement of the 
tricuspid valve into the RV, due to anomalous attachment of the tricuspid leaflets, 
resulting in tricuspid regurgitation. The abnormally situated tricuspid orifice produces 
an “atrialized” portion of the RV lying between the atrioventricular ring and the origin 
of the valve, which is continuous with the RA chamber. Often, the RV is hypoplastic.
7
  
 Risk factors for Ebstein’s anomaly include advanced maternal age (OR: 2.6, 1.4-
4.8)
142
, antihypertensive treatment during the first trimester of pregnancy (OR: 11.4, 
2.8-34.1)
135








Although the clinical manifestations are variable, some patients come to initial 
attention because of progressive cyanosis from right-to-left atrial shunting, symptoms 
due to tricuspid regurgitation and RV dysfunction or paroxysmal atrial 
tachyarrhythmias with or without Wolff-Parkinson-White syndrome. The median age at 
death is about 20 years. Surgical approaches include prosthetic replacement of the 




Total anomalous pulmonary venous return (TAPVR) 
 TAPVR accounts for 1% of all congenital heart defects. No direct 
communication exists between the pulmonary veins and the LA. Instead, they drain 
anomalously into the systemic venous tributaries or into the RA.
78
 Clinical 
manifestations differ, depending on whether there is obstruction to the pulmonary 
venous return. In patients without obstruction, CHF with growth retardation and 
frequent pulmonary infection are common in infancy and a history of mild cyanosis 
from birth is present. In patients with pulmonary venous obstruction, pulmonary arterial 
hypertension, progressive pulmonary venous congestion, hypoxemia, and systemic 
hypoperfusion occur. An interatrial communication, either an ASD or PFO, is necessary 




side of the heart is relatively small. Without surgical repair, two thirds of the infants 




 Risk factors for TAPVR include maternal age <20 years (OR: 2.3; 1.3-4.0)
105
 
and pre-gestational diabetes (OR: 7.1, 2.0-25.4).
109
 
 Corrective surgery is necessary for all patients with this condition. An office 
evaluation every 6 to 12 months is recommended for such late complications as 




Prenatal and family screening 
Fetal echocardiographic screening is indicated if either parent is afflicted with 
any form of CHD. It should be performed in a specialized center at 18-22 weeks of 
gestation.
179
Earlier fetal echocardiography may be recommended for families with high 
rates of CHD recurrence and more severe cardiac defects.
86
 Early detection of complex 
CHD can drastically improve outcomes by planning delivery in a specialized (level 3) 
tertiary care center with appropriate monitoring and early catheter-based or surgical 
interventions when indicated, reducing mortality and morbidity.
179
 Termination of a 
pregnancy can be an option if the fetus is affected.
28
 Reported pregnancy termination 
rates for severe CHD identified by prenatal screening were 45% in the Netherlands
179
 
and 86% in Switzerland.
180
 Factors associated with pregnancy termination included 




Although prenatal detection of neural tube defects is high, the sensitivity for 
detecting CHDs is still low
182
, which means that a large proportion of CHDs cannot be 
avoided by detection and termination of affected pregnancies. The couple receiving 
prenatal counseling and surveillance should be informed of the impossibility to exclude 
smaller or evolutive lesions as coarctation in examined fetuses and the final prognosis 
of the affected cases may be sometimes completed only after birth.
89
 Fetal 
echocardiography may be considered for all MC/DA twin gestations, as discussed 
before.
91
 The associations of birth defects with gestational diabetes mellitus (GDM) 
previously noticed highlight the importance of follow-up evaluation and counseling of 
women who are diagnosed with GDM during and subsequent to the index pregnancy. 
Pregnancies that are complicated by GDM among women with a history of above 
average weight before pregnancy might warrant consideration for prenatal screening for 
56 
 
malformations with ultrasound scans and fetal echocardiogram, even though the quality 




In some circumstances, prenatal or preimplantation genetic screening could 
identify fetuses or embryos at high risk for CHD. 
Fetal genetic screening for CHD is possible, including genome-wide high-
resolution SNP arrays to identify CNVs
183
 and competitive genomic hybridization to 
detect submicroscopic chromosomal aberrations.
184
 A prenatal diagnostic test can be 
performed after chorionic villus sampling before 14 weeks of gestation or through 
amniocentesis between 15 and 18 weeks of gestation. However, these procedures carry 
a fetal loss rate of 0.5-1%.
86
 Thus far, such testing has been limited to specific disease 
entities such as trisomy 21, 18, and 13, cystic fibrosis, and microdeletion syndromes 
(e.g., DiGeorge). Cytogenetic testing has been recommended as well for establishing a 
prenatal diagnosis when CHD is identified by fetal echocardiography.
17
 It has been 
recommended to screen all children with SVAS or PVS for Williams-Beuren syndrome 
(prenatal testing for 7q11.23 microdeletion) and those with an interrupted aortic arch, 
truncus arteriosus, TOF, VSD with aortic arch anomaly, isolated aortic arch anomaly, or 
discontinuous branch pulmonary arteries for DiGeorge syndrome (prenatal testing for 
22q11 deletion).
17
 It could also be performed for any severe monogenic disease if the 
result could influence the decision to terminate pregnancy.
15
  
Preimplantation diagnostic testing could be proposed in selected cases, 
particularly for women with a history of multiple therapeutic abortions. Thus, it could 
be used to identify embryos free of specific genetic abnormalities prior to embryo 
transfer for severe inherited disorders.
86
 It has already been used for Holt Oram (as it 
was referred before) and Marfan syndromes.
61
 Beyond syndromes such as trisomy 21, 
18 or 13, prenatal or preimplantation genetic screening remains controversial. Ethical 
issues may arise as a result of uncertainties in interpreting tests, potential for false 
positives, and the inability to predict disease severity, penetrance and expressivity of a 
mutation, and concordant or discordant phenotypes.
15
 
Echocardiographic screening of relatives of patients with obstructive left heart 
lesion, including BAV, CoA and/or aortic dilation without extracardiac anomalies is 
justified owing to the possibility of presence of an asymptomatic and undetetected BAV 
in the family.
99
 The rationale for family screening is that early detection may help avert 




insufficiency, endocarditis, AS and CoA, such as arterial hypertension. Early detection 
may lead to lifestyle recommendations, for example to limit isometric exercises, 
enhanced monitoring, namely for progressive aortic dilatation, or preventive surgery, 
prior to aortic dissection for example. Age at screening remains controversial. It should 
generally be proposed to adults if not previously performed during childhood.
15
 At 
present, systematic screening of first-degree relatives is not recommended for other 





 Cardiovascular genetic counseling was first recognized by the National Society 
of Genetic Counselors as a specialty in 2006. Consequently, most CHD cardiologists 
will be required to participate in the genetic counseling of their patients at some stage.
86
 
More than simply estimating the risk of recurrence in families with CHD, genetic 
counseling is a process that aims to help people understand and adapt to the medical, 
psychological and familial implications of genetic contributions to disease.
86
 
 Genetic counseling is important before and after genetic testing.
15
 Prior to 
testing, interpretation of family and medical histories should be addressed to assess the 
chance of disease occurrence or recurrence. The family should be educated about 
inheritance, testing, management, prevention, resources, and research, so that informed 
choices and adaptation to the risk or condition can be promoted.
86
 First, the patient 
should be informed of the risks of a negative result arising from the fact that all genes 
implicated in a given phenotype have not been identified. Second, the pathogenic 
potential of a genetic variant may be difficult to determine. Third, if a genetic familial 
disorder is identified, the patient is responsible for informing the family. The potential 
impact that test results may have on family dynamics should be discussed before testing 
is undertaken. Informed consent is obtained after each of these issues is addressed.
86
  
 After genetic testing, counseling is important to review the results, explain the 
genetic variant, and discuss implications with the patient and family.
185
 Given the 
complexity of the medical and ethical issues surrounding a genetic diagnosis in CHD, 






Genetic testing and indications 
Monogenic and chromosomal abnormality models account for a substantial 
proportion of CHD, which enhances the potential value of genetic investigation and 
testing.
15
 Positive consequences of genetic testing include relief of uncertainty 
surrounding a diagnosis, more accurate estimation of transmission risk, and 
identification of asymptomatic at-risk family members. Genetic confirmation may also 
enable preemptive screening and treatment of complications such as aortic dilation in 
Marfan syndrome
186
, HCM  in Noonan syndrome
187
 and neuropsychiatric disease in 
22q11.2 microdeletion syndrome.
188
Potential harms of genetic testing include difficulty 
in acquiring insurance, potential job discrimination, and negative self-image.
189
 
The selection of a genetic test is contingent upon the particular diagnostic 
hypothesis generated by clinical examination.
15
 Genetic investigation in CHD may carry 
the potential to improve prognosis by yielding valuable information regarding 
personalized medical care, confidence in the clinical diagnosis, and/or targeted patient 
followup. Moreover, genetic assessment may serve as a tool to predict recurrence risk, 
define the pattern of inheritance within a family, and evaluate the need for further 
family screening.  
The first clinical situation to consider genetic testing in CHD is the presence of a 
syndromic phenotype. As it was shown above, many syndromic conditions associated 
with CHD, such as Down, Patau, Edward, Noonan, Alagille, Williams-Beuren, Holt-
Oram and DiGeorge/VCFS syndromes, have genetic testing available in the clinical 
setting, which can confirm the diagnosis. In general, genetic consultation is 
recommended when a probable syndromic phenotype is identified.
15
 It is important to 




The second clinical situation to consider genetic testing is in the context of a 
family in which a person diagnosed with CHD has an afflicted first- or second-degree 
relative.  
The clinical investigation includes a detailed assessment of past medical, 
surgical and family histories (at least three generations to differentiate de novo from 
inherited disease).
86
 Themes that should be questioned to the families include familiar 
screening for cardiac diseases, consanguinity, particular phenotypes such as 






For non-syndromic CHD, the family tree may orient the clinician towards a 
genetic etiology and a specific pattern of inheritance. Currently, genetic testing of 
known cardiac candidate genes is not routinely recommended in the clinical setting. 
However, genetic testing of multiplex families in the context of research studies may 
identify novel mutations in known genes or entirely new causal genes. Identification of 




Specific genetic tests include search for chromosomal anomalies, such as 
trisomy 21, 18, 13 or monosomy X (Turner syndrome) through karyotype analysis. 
Fluorescence in situ hybridization (FISH) is the predominant technique used to identify 
Williams-Beuren, DiGeorge, and Alagille syndromes. Subtelomere FISH analyses are 
less commonly used today and detect abnormalities in subtelomere and telomere DNA 
regions.
17
 These studies should be ordered if the karyotype is normal in a patient with 
dysmorphic facial features, congenital anomalies, developmental delay, and mental 
retardation. Subtelomeric anomalies have been reported in patients with a syndromic 
phenotype associated with facial dysmorphia and mental retardation combined with 
CHD such as VSD, ASD, pulmonary stenosis, and right sided aortic arch.
190
 As many as 
50% of families can have other individual members with subtelomeric abnormalities.
191
  
Array-based comparative genomic hybridization (aCGH) is used to detect 
structural and numerical chromosomal abnormalities. It may be particularly useful when 
a probable chromosomal syndrome is identified but the karyotype is normal and there is 
no known specific region to test.
15
 Furthermore, this method is of additional value in 
detecting CNVs such as in screening for DiGeorge syndrome when the karyotype and 
22q11 microdeletion analyses by FISH are unrevealing.
15
 Gene sequencing through 
Next-generation sequencing technologies target coding and non-coding parts of the 
genome and can be helpful in conditions such as Noonan syndrome, Alagille syndrome 




Genes and prognosis 
The genetic environment could modulate the prognosis of various forms of 
CHD, helping to elucidate risks of developing some defects, such as conduction defects 
and systolic disfunction (NKX2.5 mutations associated with ASD, atrioventricular block 
and dilated cardiomyopathy)
192
 and diastolic dysfunction (TBX5 gene, implicated in 
Holt-Oram syndrome). Genes implicated in RASopathy syndromes (members of the 
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RAS-MAPK pathway), responsible for Noonan, cardiofaciocutaneous, Costello and 




TBX20 mutation may have an underlying ASD, VSD or mitral valve disease or 
may present exclusively with pulmonary hypertension or cardiomyopathy.
193
Mutations 
in MYH6 (alpha-cardiac myosin heavy chain) are associated with various forms of CHD 
but also dilated and hypertrophic cardiomyopathy.
194
 Moreover, mutations in MYH7 
have been reported in patients with autosomal dominant inheritance Ebstein’s anomaly 
and left ventricular noncompaction.
195
 Some family members may have CHD whereas 
others could develop progressive cardiomyopathy or electrophysiologic disorders.  
22q11.2 deletion (DiGeorge syndrome) in patients with TOF predicts a longer 
cardiopulmonary bypass time and a greater length of stay in intensive care.
196
 While 
several explanations have been proposed, potential factors include a higher prevalence 
of aortopulmonary shunts and respiratory problems prior to surgical repair in these 
patients, resulting in longer mechanical ventilatory support. Therefore, one can predict 
that genetic profile may be used in the future for pre-operative risk assessment.
15
 
The interpretation of genetic tests must be carefully assessed and placed in 
context of the clinical and family evaluation, because genetic variants may be identified 




Limitations of genetics in CHD 
Despite the fact that CHD is the most common birth defect, genetic etiology 
remains unknown in the majority of cases, with slower progress than for other forms of 
heart disease such as inherited arrhythmia syndromes and hypertrophic and dilated 
cardiomyopathy. Families with recurrent CHD and strong phenotypic penetrance were 
the most used cases in genetic studies, which represent the minority of cases of CHD.
197
 
The relatively low familial recurrence risk may be due, in part, to de novo mutations, 
incomplete penetrance, and other etiological factors such as environmental influences. 
 In the presence of environmental interactions, incomplete penetrance and 
variable expressivity, patterns of inheritance may be difficult to find. Moreover, a large 
number of members with consanguinity is required for genetic analysis based on 
individual families.
198
 The functional validation of mutations that may involve non-
coding regions of the DNA, which was reported as having a role in CHD, is more 




genetics. Rare and unique mutations to individual families can complicate as well the 
establishment of genotype-phenotype correlations. In fact, most CHD mutations 
identified to date appear to be private or do not recur. Notwithstanding these limitations, 
genetics has and will hopefully continue to provide insights into the etiology of CHD, 





Prevention of CHD 
 According to the present information regarding environmental factors associated 
with CHD, some principles for prevention could be useful. In fact, parents should be 
advised for the following measures. The use of a multivitamin containing folate daily in 
the pre- and peri-conception period is highly recommended, as well as ensuring that 
rubella vaccination has been completed before pregnancy. Avoidance of individuals 
with flu or febrile illness to minimize the chance of infection, avoidance of organic 
solvents, and avoidance of alcohol, tobacco, and illicit drugs are also important things to 
have in mind. Health care providers should provide close monitoring of women 
receiving regular medications, such as thalidomide, antihypertensives, anticonvulsivants 
and anti-inflammatory drugs, among others, and even over-the-counter medications. 
 Careful management of women with phenylketonuria and diabetes should be 
pursued, through maintenance of good glycaemic control in mothers with diabetes.
10
 A 
diagnosis of gestational diabetes mellitus (GDM) actually may represent undiagnosed 
type 2 DM and GDM is associated with an increased risk of GDM in subsequent 
pregnancies and with type 2 DM later in life. Therefore, women who are diagnosed with 
GDM might benefit from follow-up evaluations, family planning, and counseling 
regarding diabetes mellitus management if they are found to have type 2 DM and of 
diabetes mellitus prevention education otherwise.
109
 
 In addition, screening for CHDs should be performed when these situations or 
exposures are present. 
   
Conclusion 
Although much remains to be discovered in the world of CHD genetics, recent 
advances in technology provide us with the potential to better understand the etiology of 
CHD and the various phenotypes. Revolutionary genetic techniques still harbor many 
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challenges, including the difficulty in distinguishing benign variants from disease 
causing mutations, but the possible identification of disease etiology greatly outweighs 
these challenges. Novel genetic tests, including prenatal ones, are becoming gradually 
available, allowing families to plan and prepare themselves in advance, as well as to 
reduce anxiety from the possibility of having offspring with CHD. Genetic diagnosis 
and the assessment of risk for syndromic patients are important in order to effectively 
plan the surgical and medical management and multidisciplinary follow-up, helping in 
the reduction of mortality and morbidity. 
An accurate family history can provide valuable clues about possible causation 
and inheritance, which is particularly relevant to families with multiple affected 
individuals, and a referral to a genetics service should be considered.
10
 Working alone 
or in collaboration with clinical geneticists and genetic counselors, adult CHD 
specialists will continue to play an important role in identifying patients who may 
benefit from genetic testing, and in caring for those patients.  
Although significant associations between multiple non-genetic risk factors and 
CHDs have been identified, many of these risk factors have yielded conflicting results. 
Gene/environment interactions are still poorly understood as well, suggesting that 
additional investigations need to be performed.  
Finally, researchers and physicians will need to translate genetic findings and the 
new pathophysiological insights into meaningful medical advances, such as the 
development of new potential therapeutic targets in long-term to prevent or repair heart 
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